All Scientific Posters have been arranged into the following categories and numbers:

<table>
<thead>
<tr>
<th>Category</th>
<th>Poster Number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ARV-based Prevention</strong></td>
<td></td>
</tr>
<tr>
<td>Mother-to-child Transmission</td>
<td>P001–P009</td>
</tr>
<tr>
<td>Pep/PrEP</td>
<td>P010–P017</td>
</tr>
<tr>
<td>Treatment as Prevention (TasP)</td>
<td>P018–P020</td>
</tr>
<tr>
<td><strong>Treatment Strategies</strong></td>
<td></td>
</tr>
<tr>
<td>New Treatments and Targets</td>
<td>P021–P029</td>
</tr>
<tr>
<td>Target Populations</td>
<td></td>
</tr>
<tr>
<td>Adolescents and Children</td>
<td>P031–P034</td>
</tr>
<tr>
<td>Women</td>
<td>P035–P039</td>
</tr>
<tr>
<td>Late Presenters</td>
<td>P040–P042</td>
</tr>
<tr>
<td>Naïve Patients</td>
<td>P043–P049</td>
</tr>
<tr>
<td>Primary Infection</td>
<td>P050–P053</td>
</tr>
<tr>
<td>Experienced Patients</td>
<td>P054–P060</td>
</tr>
<tr>
<td>IDUs</td>
<td>P061–P065</td>
</tr>
<tr>
<td>Strategies</td>
<td></td>
</tr>
<tr>
<td>Adherence</td>
<td>P066–P076</td>
</tr>
<tr>
<td>Cure</td>
<td>P077–P079</td>
</tr>
<tr>
<td>Simplification</td>
<td>P080–P092</td>
</tr>
<tr>
<td>Switch Studies</td>
<td>P093–P113</td>
</tr>
<tr>
<td>Other</td>
<td>P114–P141</td>
</tr>
<tr>
<td><strong>Opportunistic Infections</strong></td>
<td></td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>P142–P149</td>
</tr>
<tr>
<td>Others</td>
<td>P150–P152</td>
</tr>
<tr>
<td><strong>Co-morbidities and Complications of Disease and/or Treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Ageing</td>
<td>P153–P168</td>
</tr>
<tr>
<td>Bone</td>
<td>P169–P173</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>P174–P188</td>
</tr>
<tr>
<td>Malignancies</td>
<td></td>
</tr>
<tr>
<td>AIDS-defining</td>
<td>P189–P191</td>
</tr>
<tr>
<td>Non-AIDS-defining</td>
<td>P192–P199</td>
</tr>
<tr>
<td>Metabolic</td>
<td>P200–P207</td>
</tr>
<tr>
<td>Neurological</td>
<td>P208–P217</td>
</tr>
<tr>
<td>Renal</td>
<td>P218–P227</td>
</tr>
<tr>
<td>Other</td>
<td>P228–P247</td>
</tr>
<tr>
<td>Category</td>
<td>Pages</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Viral Hepatitis</td>
<td>P248–P300</td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
<td>P301–P319</td>
</tr>
<tr>
<td>Community Initiatives</td>
<td>P320–P324</td>
</tr>
<tr>
<td>Models of Care</td>
<td></td>
</tr>
<tr>
<td>Cost-effectiveness</td>
<td>P327–P331</td>
</tr>
<tr>
<td>Evaluation of ARV Delivery and Coverage</td>
<td>P332–P339</td>
</tr>
<tr>
<td>Late Presenters</td>
<td>P340–P344</td>
</tr>
<tr>
<td>Virology and Immunology</td>
<td></td>
</tr>
<tr>
<td>Biomarkers/Tropism</td>
<td>P345–P351</td>
</tr>
<tr>
<td>Resistance</td>
<td>P352–P370</td>
</tr>
<tr>
<td>Other</td>
<td>P371–P374</td>
</tr>
</tbody>
</table>
## POSTER PRESENTATIONS (continued)

### ARV-based Prevention

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P001</td>
<td>High prevalence of hepatitis C co-infection and adverse pregnancy outcomes among HIV-infected pregnant women in Switzerland</td>
<td>Aebi-Popp, K*; Glass, T; Rudin, C; Martinez de Tejada, B; Hoesli, I; Grawe, C; Fischer, T; Duppenthaler, A; Rauch, A; Kahlert, C (Bern, Switzerland)</td>
</tr>
<tr>
<td>P002</td>
<td>A mother-to-child HIV-1 transmission bottleneck? A new understanding of the selection biases underlying successful perinatal infection</td>
<td>Noble, C*; Adland, E; Naidoo, V; Ndung’u, T; Goulder, P (Oxford, UK)</td>
</tr>
<tr>
<td>P003</td>
<td>Raltegravir in HIV-1-infected pregnant women: mother-to-child transmission (MTCT) prophylaxis and children safety case series</td>
<td>Soares Medeiros, M*; Pires Moreira, H; Antonio Gomes Arruda, E; Austregesilo Correa, E; Camel de Sales, Y; Facanha Diogenes Teixeira, G; Aragao Ribeiro, E; Silveira Dantas, R (Fortaleza, Brazil)</td>
</tr>
<tr>
<td>P004</td>
<td>Prophylactic antiretroviral treatment in new-born infants from HIV-positive mothers in 2012–2015, for the North-Eastern part of Romania</td>
<td>Manciuc, C; Vata, A; Nicolaou, C*; Largu, A (Iasi, Romania)</td>
</tr>
<tr>
<td>P005</td>
<td>Determinants and risk of HIV infection among HIV-exposed infants in Western Ethiopia</td>
<td>Duken, E*; Regea, D; Siyum, O (Jimma, Ethiopia)</td>
</tr>
<tr>
<td>P006</td>
<td>Preventing mother-to-child transmission of HIV in a general hospital: are we following the guidelines?</td>
<td>Awosusi, F*; Al-Harbi, M (London, UK)</td>
</tr>
<tr>
<td>P007</td>
<td>Influence of HIV infection in choosing to terminate pregnancy</td>
<td>Campoa, E*; Pedro, L; Azevedo, F; Pinho, R; Simão, M; Santos, C; Faria, D; Santos, C; Arez, L (Portimão, Portugal)</td>
</tr>
<tr>
<td>P008</td>
<td>The association between preterm delivery and the risk of mother-to-child transmission of HIV</td>
<td>Posokhova, S*; Petrovych, S; Shevchenko, S (Odessa, Ukraine)</td>
</tr>
<tr>
<td>P009</td>
<td>Efficacy of prophylactic antiretroviral treatment in new-born infants from HIV-positive mothers in 2012–2014, for the North-Eastern part of Romania</td>
<td>Manciuc, C; Prisacariu, L; Nicolaou, C*; Largu, A (Iasi, Romania)</td>
</tr>
<tr>
<td>P010</td>
<td>Compliance of fixed-dose single tablet EVG/COBI/FTC/TDF (Stribild) regimen versus LPV/r/d4T/3TC for PEP in sexual assault victims: a retrospective sequential period study</td>
<td>De Wit, S; Libois, A*; Mois, P; Malinverni, S (Brussels, Belgium)</td>
</tr>
<tr>
<td>P011</td>
<td>Increased rate of Chlamydia trachomatis infection after being prescribed PrEP</td>
<td>Nguyen, V; Trottier, H; Gbego Tossa, H; Charrest, L; Longpré, D; Lavoie, S; Cadieux, M; Thomas, R* (Montréal, Canada)</td>
</tr>
<tr>
<td>P012</td>
<td>Risk perception in MSM taking PrEP</td>
<td>Boccino, S; Kanagalinghan, U; Nwokolo, N*; Whitlock, G (London, UK)</td>
</tr>
<tr>
<td>P013</td>
<td>Attitudes towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counseling and testing for HIV in Taiwan</td>
<td>Chang, L; Liu, W; Wu, C; Lee, Y; Sun, H; Hung, C*; Chang, S (Taipei, Taiwan)</td>
</tr>
<tr>
<td>P014</td>
<td>‘Self-perceived’ pre-exposure prophylaxis adherence and its relationship to self-reported ‘actual adherence’ among Thai men who have sex with men and transgender women</td>
<td>Anand, T*; Kerr, S; Apompong, T; Nitpolprasert, C; Anaworanich, J; Phanuphak, P; Phanuphak, N (Bangkok, Thailand)</td>
</tr>
</tbody>
</table>

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P015  Polish infectious diseases physicians’ attitudes and beliefs about pre-exposure prophylaxis for HIV prevention
Kolodziej, J; Mikula, T; Wiercinska-Drapalo, A* (Warsaw, Poland)

P016  Pre-exposure prophylaxis awareness in individuals accessing a non-occupational post-exposure prophylaxis (NPEP) program
Peel, J*; Lachowsky, N; Moore, D; Jabbari, S; Zhang, W; Guillen, S; Harris, M; Greenan, T; Wong, J; Montessori, V; Ogilvie, G; Montaner, J; Hull, M (Vancouver, Canada)

P017  PrEP use in Lisbon while waiting for a policy
Meireles, P; Rocha, M*; Campos, M; Barros, H (Lisbon, Portugal)

P018  Increasing ART coverage and viral suppression are associated with a substantial decline in new HIV infections in the Austrian Tyrol
Leierer, G*; van Sighern, A; Sarcletti, M; Kitchen, M; Gisinger, M; Rappold, M; Ledergerber, B; Zangerle, R (Innsbruck, Austria)

P019  Implementation of isoniazid preventive therapy for people living with HIV in Northwestern Nigeria: integration challenges and issues
Adepoju, A*; Egesemba, G; Kangiwa, U; Igene, P (Birnin Kebbi, Nigeria)

P020  Cascade of care in TAK project: strong in right side, but weak in left side
Kowalska, J*; Shepherd, L; Ankiersztejn-Bartczak, M; Firlag-Burkacka, E; Horban, A; Mocroft, A (Warsaw, Poland)

Treatment Strategies

P021  Durability and tolerability of first-line combination including two NRTIs and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort
d’Arminio Monforte, A*; Lorenzini, P; Cozzi-Lepri, A; Mussini, C; Castagna, A; Baldelli, F; Puoti, M; Mazzotta, F; Abrescia, N; Lo Caputo, S; Gianotti, N; Antinori, A; on behalf of the ICONA Foundation cohort (Milan, Italy)

P022  HIV-1 combinetin GSK3732394: a long-acting inhibitor with multiple modes of action
Krystal, M*; Wensel, D; Sun, Y; Davis, J; McDonagh, T; Li, Z; Zhang, S; Soars, M; Cockett, M (Wallingford, USA)

P023  Mono- and dual suppressive antiretroviral regimens in a real-life setting: the experience of Pitié Salpêtrière HIV Centre
Caby, F*; Agher, R; Tubiana, R; Blanc, C; Jaspard, M; Doutot, Y; Calin, R; Calvez, V; Simon, A; Valantin, M; Katlama, C (Paris, France)

P024  Safety and antiviral effect of elpida (VM-1500), a novel NNRTI (+truvada) in treatment-naïve HIV-1-infected patients at 24–48 weeks of therapy
Kravchenko, A*; Orlova-Morozova, E; Nagimova, F; Shimonova, T; Bichko, V; Vostokova, N; Zozulya, O (Moscow, Russian Federation)

P025  The integrase strand transfer inhibitor bictegravir has a long integrase/DNA dissociation half-life
White, K*; Majka, A; Novikov, N; Miller, M; Tsiang, M (Foster City, USA)

P026  Durability and prescribing patterns of initial HIV regimens in treatment-naïve patients
Eatmon, E; Tamhane, A; Prajapati, G*; Goodwin, B; Saag, M (Rahway, USA)

P027  Integrase inhibitor-based antiretroviral therapy in vulnerable populations
Conway, B; Kiani, G*; Shahi, R; Raycraft, T; Singh, A; Hakobyan, S; Alimohammadi, A (Vancouver, Canada)

*Indicates presenting author.
P028  Inhibition of HIV-1 protease and plasmodium falciparum by a modified digold chloroquine derivative  
Gama, N*; Kumar, K; Reader, J; Gordhan, B; Birkholtz, L; Kana, B; Darkwa, J; Meyer, D (Pretoria, South Africa)

P029  Treatment failure of chronic HCV infection with the new direct-acting antivirals: experience of a Portuguese central hospital  
Pereira, K*; Dias Grazina, S; Miranda, A; Baptista, T; Borges, F; Nina, J; Peres, S; Aldir, I; Campos, M; Antunes, I; Pereira, J; Ventura, F; Mansinho, K (Lisbon, Portugal)

P031  Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations in routine care of HIV-infected children with diverse ethnic origin  
Soeria-Atmadja, S*; Österberg, E; Gustafsson, L; Dahl, M; Eriksen, J; Rubin, J; Navér, L (Stockholm, Sweden)

P032  Relative bioavailability and food effect of a paediatric dispersible tablet formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV)  
Crauwels, H*; Goyvaerts, N; Vanveggel, S; Van Solingen, R (Beerse, Belgium)

P033  Predictors of plasma HIV RNA suppression in a cohort of perinatally HIV-infected individuals  
Contreras, G*; Rodriguez, G; Del Bianco, G; Perez, N; Benjamins, L; Murphy, J; Heresi, G (Houston, USA)

P034  Characteristics and outcome of HIV-positive children internationally adopted in France  
Lesens, O*; Blanche, S; Corbin, V; Jacomet, C (Clermont-Ferrand, France)

P035  Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): subgroup analyses  
Johnson, M*; Gatey, C; Manosuthi, W; Lazzarin, A; Podzamczer, D; Man, C; Aylott, A; Buchanan, A; Wynne, B; Vavro, C; Aboud, M; Smith, K (London, UK)

P036  Sex and gender differences in rilpivirine-based ART: data from the HIV Center Frankfurt  
Schüttert, G*; Philipp, K; Brodt, H; de Leuw, P; Göpel, S; Hermann, E; Khaykin, P; Stephan, C; Wolf, T; Haberl, A (Frankfurt am Main, Germany)

P038  Treatment outcomes and co-morbidities in German female HIV-infected patients in 2015: a comparison to 2008 and to a male population  
Roemer, K*; Usadel, S; Graefe, K; Steib-Bauert, M; Speer, M; Fischer, S; Hanhoff, N; Knecht, G (Cologne, Germany)

P039  Discontinuation of first-line ART is associated with female sex and migration background: data from a German outpatient clinic  
Bilinski, S*; De Leuw, P; Göpel, S; Khaykin, P; Schüttert, G; Brodt, H; Wolf, T; Stephan, C; Hermann, E; Haberl, A (Frankfurt, Germany)

P040  Risk factors for late presentation over the last 6 years in Athens, Greece (2009–2015)  
Spanos, A; Kavatha, D; Protopapas, K*; Siakalis, G; Argyropoulou, M; Moschopoulos, C; Antalis, E; Fragkou, P; Melachrinopoulos, N; Tsiodras, S; Antoniadou, A; Papadopoulos, A (Athens, Greece)

P041  Late presenters: how do they look after ART nowadays?  
Oliveira Paulo, C*; Duarte, F; Ruiz Pena, E; Guimarães, M; Correia Abreu, R; Jordao, S; Neves, I (Matosinhos, Portugal)

P042  The utility of enfuvirtide revisited  
Pinho, R*; Campoea, E; Faria, D; Santos, C; Arez, L (Portimão, Portugal)

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P043  Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naïve patients
Abram, M; Ram, R; White, K; Miller, M; Callebaut, C* (Foster City, USA)

P044  Does ethnic origin influence timing, choice and response to first-line antiretroviral therapy in France?
Gatey, C*; Brun, A; Turpault, I; Sellier, P; Bouchaud, O; Patay, O; Garratt, V; Jeanlils, V; Chabrol, A; Diamantis, S; Gregoire-Faucher, V; Froguel, E; Son, O; Lamy, S; Routier, C; Ait Mohand, H; Turner, L; Hamet, G; Delaegerre, C; Rozenbaum, W; Molina, J; and the COREVIH Ile de France (Paris, France)

P045  Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve Asian adults
Oka, S*; Chetchotisakd, P; Clarke, A; Supparatpinyo, K; Kiertiburanakul, S; Ryu, J; Piontkowsky, D; Guo, S; Nguyen-Cleary, T; Das, M; McCallister, S (Tokyo, Japan)

P046  Combining lopinavir/r with new ARV agents in ART-naïve HIV-infected patients: data from the German multicenter PROTEKT cohort
Wolf, E; Hillenbrand, H; Baumgarten, A; Stephan, C; Lutz, T; Koepppe, S; Huelsenbeck, J* (Wiesbaden, Germany)

P047  Outcome of antiretroviral regimens prescribed by following the regulations on combination antiretroviral therapy by Taiwan Centers for Disease Control
Tsai, M*; Yang, C; Zhang, J; Wu, P; Yang, S; Luo, Y; Chang, H; Lin, K; Sun, H; Hung, C (New Taipei City, Taiwan)

P048  Prescription pattern and determinants of dolutegravir use in an antiretroviral-naïve HIV-infected population in Italy: data from the ICONA Foundation cohort
Antinori, A*; Cozzi Lepri, A; Castagna, A; Lo Caputo, S; Mussini, C; Rusconi, S; Di Biagio, A; Marchetti, G; Nozza, S; Cingolani, A; De Luca, A; d’Arminio Monforte, A; on behalf of the ICONA Foundation cohort (Rome, Italy)

P049  The RESINA data support the individualized therapy based on primary resistance testing
Knops, E*; Schuelter, E; Luebke, N; Neumann-Fraune, M; Heger, E; Sierra-Aragon, S; Mueller, C; Oette, M; Faetkenheuer, G; Hower, M; Krechtlen, H; Schuebel, N; Esser, S; Scholten, S; Haeussinger, D; Kaiser, R; Jensen, B (Cologne, Germany)

P050  The acute/recent HIV infection cohort from Hospital Clinic, Barcelona: epidemiological trends and evolution from 1997 to 2015
Nicolas Ocejo, D*; Ambrosioni, J; Manzardo, C; Agüero, F; Mosquera, M; Parera, M; Sanchez-Palomino, S; Ligero, C; Fernandez, E; de Lazzari, E; Plana, M; Gatell, J; Miró, J (Barcelona, Spain)

P051  Neurological involvement in patients with acute/recent HIV-1 infection
Artigues, F; Ambrosioni, J*; Nicolás, D; Peñafiel, J; Agüero, F; Manzardo, C; Mosquera, M; Sánchez-Palomino, S; de Lazzari, E; Marcos, M; Plana, M; Miro, J (Barcelona, Spain)

P052  Single-tablet regimen with elvitegravir, cobicistat, emtricitabine and tenofovir for the treatment of early HIV infection
Teira, R*; Galindo, M; Montero, M; Portilla, R; Ferrer, A; Martinez, E (Torrelavega, Spain)

P053  Comparison of (TDF+FTC) associated with either darunavir/ritonavir+raltegravir or dolutegravir: virological efficacy of two different treatment strategies for primary HIV infection (PHI)
Pinnetti, C*; Abbate, I; Lorenzini, P; Orchi, N; Gori, C; Amendola, A; Libertone, R; Rozera, G; Plazzi, M; Fabbri, G; Capobianchi, M; Antinori, A; Ammassari, A (Rome, Italy)

*Indicates presenting author.
P054 Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: preliminary results at 24 weeks of the DORIVIR study
Palacios, R*; Mayorga, M; González-Domenech, C; Hidalgo-Tenorio, C; Gálvez, C; Muñoz-Medina, L; de la Torre, J; Lozano, A; Castaño, M; Omar, M; Santos, J (Málaga, Spain)

P055 Efficacy, safety and patient-reported outcomes from treatment-experienced subjects in routine clinical practice switching to EVG/COBI/FTC/TAF (Genvoya®): the German TAFNES cohort
Schleenvoigt, B*; Jessen, H; Waizmann, M; Pauli, R; Rieke, A; Postel, N; Heuchel, T; Schulz, C; Mueller, M; Moll, A; Stephan, C; Spinner, C; Haubrich, R; Heinzkill, M; Wieszner, C; Stellbrink, H (Jena, Germany)

P056 Frailty improves in both young and old HIV patients undergoing atazanavir-based regimens
Guaraldi, G*; Malagoli, A; Dolci, G; Carli, F; Menozzi, M; Santoro, A; Zona, S; Mussini, C (Modena, Italy)

P057 High-level HIV drug resistance mutations in patients with unsuppressed viral load from Northern South Africa
Etta, E*; Manhaeve, C; McGonigle, K; Rekosh, D; Hammarskjold, M; Tebit, D; Bessong, P (Charlottesville, USA)

P058 Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT)
Marshall, N; McNulty, M; Smith, C; Swaden, L; Burns, F; Orkin, C* (London, UK)

P059 Long-term virological outcomes of replacing zidovudine or stavudine with tenofovir in the absence of routine virological monitoring in Kumasi, Ghana
Villa, G*; Phillips, R; Smith, C; Stockdale, A; Beloukas, A; Appiah, L; Chadwick, D; Ruggiero, A; Sarfo, F; Geretti, A (Liverpool, UK)

P060 Non-adherence in HIV patients is caused by specific reasons: results from the German adherence cohort study
Boretzki, J; Wiese, C; Oldenbuettel, C; Krznaric, I; Meurer, A; Zink, A; Lersch, C; Balogh, A; Wolf, E; Spinner, C* (Munich, Germany)

P061 Prevalence of HIV virological failure in a multidisciplinary centre treating high-risk vulnerable populations
Almohammadi, A*; Raycraft, T; Kiani, G; Shahi, R; Singh, A; Hakobyan, S; Conway, B (Vancouver, Canada)

P062 Methadone maintenance treatment and efficiency of ART in HIV-positive injecting drug users in the Ukraine
Zhyvytsia, D*; Kazeka, V (Zaporizhia, Ukraine)

P063 Community pharmacy dispensed ART alongside opiate replacement therapy in Glasgow's HIV outbreak
Peters, S; Brown, K*; Laird, A; Gillespie, R; Thomson, D; Milosevic, C (Glasgow, UK)

P064 HIV testing and care in prisoners: the first year results of opt-out BBV testing in Glasgow, UK
Peters, S*; Bissett, B; Cassells, Y; Paton, J; Aitken, C (Glasgow, UK)

P065 Correlates of HIV virological non-suppression at a tertiary clinic
Singh, A*; Raycraft, T; Almohammadi, A; Kiani, G; Shahi, R; Conway, B (Vancouver, Canada)

*Indicates presenting author.
**POSTER PRESENTATIONS (continued)**

| P066 | The effect of relationship status and housing stability on adherence to combination antiretroviral therapy among people living with HIV who use illicit drugs in British Columbia, Canada  
Singh, A*; Salters, K; Parashar, S; Puskas, C; Wang, L; Montaner, J; Hogg, R; Samji, H (Burnaby, Canada) |
| P067 | HIV support group within a multidisciplinary healthcare delivery model as a treatment strategy for people who inject drugs  
Shahi, R*; Kiani, G; Alimohammadi, A; Raycraft, T; Singh, A; Hakobyan, S; Conway, B (Vancouver, Canada) |
| P068 | Adherence to cART and low-level viremia in a large single-center clinical cohort  
Maggiolo, F*; Di Filippo, E; Calegaro, A; Colombo, G; Di Matteo, S; Valenti, D; Rizzi, M (Bergamo, Italy) |
| P069 | Developing a patient-reported outcome measure (PRO) for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through typological analysis  
Toupin, I*; Engler, K; Lessard, D; Lénart, A; Raffi, F; Spire, B; Lebouché, B (Montreal, Canada) |
| P070 | Patient acceptance of a web-linked smartphone app to assess treatment compliance in HIV-infected subjects: a pilot study  
Sala-Piñol, F*; Andreu-Crespo, A; Llibre, J; Coll, J; Grasa, J; Calvet, A; Clotet, B; Bonafont-Pujol, X (Barcelona, Spain) |
| P071 | The moderating role of treatment engagement on the relationship between neurocognitive impairment and antiretroviral treatment (ART) adherence  
Shrestha, R*; Karki, P; Huedo-Medina, T; Copenhagen, M (Farmington, USA) |
| P072 | Real-world persistence and outcomes for HIV-1 treatment: single- versus multiple-tablet regimen comparison  
Sweet, D; Budd, D*; Cohen, J (Foster City, USA) |
| P073 | Factors influencing clinicians’ choices of ARVs in the USA  
Hahn, R; Goodwin, B; Hogue, S; Murray, M*; Davis, K (Brentford, UK) |
| P075 | MATH study: migrants adherence to therapy at an HIV outpatient clinic  
Rodrigues, C*; Martins, Y; Caixas, U; Lampreia, F; Germano, I (Lisbon, Portugal) |
| P076 | Predictors of retention to care among HIV-infected patients in Northern Greece  
Tsachouridou, O*; Christaki, E; Skoura, L; Rana, A; Zampakis, P; Metallidis, S (Thessaloniki, Greece) |
| P077 | Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation  
Knops, E*; Kobbe, G; Kaiser, R; Luebke, N; Dunay, G; Wensing, A; Martinez-Picado, J; Nijhuis, M; Fischer, J; Huettig, F; Haas, R; Haeusinger, D; Jensen, B (Cologne, Germany) |
| P078 | Differential efficacy of ABX464 and its primary metabolite ABX464-NGlc on HIV replication in human PBMCs and macrophages: implications for treatment strategies to eliminate virus reservoirs  
Scherrer, D*; Steens, J; Gineste, P; Campos, N; Garcel, A; Schlaefper, E; Speck, R; Tazi, J; Ehrlich, H (Paris, France) |
| P079 | Development of methods for in vitro reactivation of latent reservoir of HIV-1 infection in patients under suppressive HAART  
Jadav, G* (Siena, Italy) |

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P080  Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment-experienced HIV-infected patients: 48-week results from a pilot study (DOLULAM)
Reynes, J*; Meftah, N; Montes, B (Montpellier, France)

P081  Efficacy of antiretroviral drugs during intermittent maintenance treatment with a 4-days-a-week regimen despite low plasma concentrations (ANRS 162-4D trial)
Alvarez, J*; De Truchis, P; Abe, E; Assoumou, L; Landman, R; Mathez, D; Amat, K; Kattama, C; Girard, P; Le Du, D; Duracinsky, M; Costagliola, D; Bellet, J; Perronne, C (Garches, France)

P082  Dual therapy with non-boosted atazanavir plus lamivudine is an effective simplification strategy for virologically stable patients with HIV
Pasquau, J; de Jesús, S*; García-Vallecillos, C; Hidalgo-Tenorio, C (Granada, Spain)

P083  Lamivudine + dolutegravir as simplification strategy in patients with suppressed HIV RNA
Maggiolo, F*; Guiminetti, R; Mussini, C; Pagnucco, L; Digaetano, M; Benatti, S; Valenti, D; Ripamonti, D (Bergamo, Italy)

P084  In monotherapy, darunavir/cobicistat demonstrates equivalence to darunavir/ritonavir, and in selected patients is as effective as bitherapies or triple therapies
Pasquau, J; García-Vallecillos, C; Crucès-Moreno, M; de Jesus, S*; Fatoul del Pino, G; Hidalgo-Tenorio, C; Vinuesa-García, D; López-Ruz, M; Hernández-Quero, J (Granada, Spain)

P085  Darunavir/cobicistat as antiretroviral treatment simplification strategy in patients with stable monotherapy with ritonavir-boosted protease inhibitors in the clinical setting
Santos, J*; Peláez Ibañez, P; Bravo, I; Llibre, J; Paredes, R; Clotet, B; Moltó, J (Barcelona, Spain)

P086  3-year efficacy and durability of simplification to a single-tablet regimen (STR): a comparison between coformulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir
Gagliardini, R*; Bandera, A; Zaccarelli, M; Sterrantino, G; Latin, A; D’Avino, A; Picarelli, C; Lapadula, G; Antinori, A; Cauda, R; De Luca, A; Gori, A; Di Giambenedetto, S; Fabbiani, M (Rome, Italy)

P087  Efficacy and safety of switch from DRV/r to DRV/COBI in HIV monotherapy
Gutiérrez Liarte, A*; Gómez Berrocal, A; De Miguel Buckley, R; Sanz Sanz, J (Madrid, Spain)

P088  Efficacy of dual therapy with rilpivirine and boosted darunavir in treatment-experienced HIV patients
Pasquau, J; de Jesús, S*; Hidalgo-Tenorio, C; Arazo, P; Crussells, M; Rios, M; Lozano, F; de la Torre, J; Tornero, C; García-Vallecillos, C; Verdejo, G; Palacios, Z; Samperiz, G; Galindo, M; Terron, J; García-Deltoro, M (Granada, Spain)

P089  Simplification to dual protease inhibitor (PI)-, integrase strand transfer inhibitor (INSTI)- and non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based less drugs regimens in treatment-experienced HIV-1-infected patients
Mastroianni, A*; Briganti, E; Allegrini, F; Grosso, C; Brighi, S; Ravaglia, G; Pieraccini, F; Cancellieri, C (Forlì, Italy)

P090  Dolutegravir and unboosted atazanavir: a dual NRTI- and booster-free antiretroviral regimen simplification in HIV-1-infected patients with viral suppression
Riva, A*; Poli, A; Rusconi, S; Bonora, S; Cattelan, A; Quiros Roldan, E; Ferrara, M; Spagnuolo, V; Pagnucco, L; Cavinato, S; Cattaneo, D; Guiminetti, R; Castagna, A (Milan, Italy)

P091  Treatment of HIV-positive patients with lamivudine plus boosted protease inhibitor in a real-world setting
Cheng, C*; Cheng, S; Chang, S; Lin, M; Ku, S; Shieh, H; Sun, N (Taoyuan City, Taiwan)

*Indicates presenting author.
P092 Effectiveness and convenience of ATV/r+3TC dual therapy regimen in a real-life cohort of HIV-infected patients: 48-week follow-up
Ferrara, S*; Tartaglia, A; Sica, S; Santantonio, T (Foggia, Italy)

P093 Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent
Post, F*; Yazdanpanah, Y; Schembri, G; Lazzarin, A; Reynes, J; Maggiolo, F; Yan, M; Abram, M; Tran-Muchowski, C; Cheng, A; Rhee, M (London, UK)

P094 Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch
Dickinson, L*; Bracchi, M; Elliot, E; Else, L; Khoo, S; Back, D; Nelson, M; Boffito, M (Liverpool, UK)

P095 Virological response of HIV-infected patients virologically suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score
Charpentier, C*; Peytavin, G; Joly, V; Cabras, O; Perrier, M; Lé, M; Phung, B; Yazdanpanah, Y; Descamps, D; Landman, R (Paris, France)

P096 Evaluation of virologic efficacy and economic savings in a Portuguese hospital after splitting the single-tablet regimen EFV/FTC/TDF (Atripla®) to an equivalent double-tablet regimen (efavirenz+Truvada®)
Guimarães, M*; Vaz Pinto, I; Santos, C; Alves, S (Cascais, Portugal)

P097 Dolutegravir plus ritonavir-boosted darunavir in highly cART-experienced subjects: an observational cohort
Capetti, A*; Sterrantino, G; Cossu, M; Cenderello, G; Rusconi, S; Cima, S; Baldin, G; Cattelan, A; De Socio, G; Riccardi, N; Orofino, G; Celesia, B; Niero, F; Sasset, L (Milan, Italy)

P098 A retrospective analysis to evaluate and compare the efficacy of switching to stridib fixed-dose combination in virologically-suppressed HIV-1-infected adults with or without the archived NRTI-resistance mutation M184V/I
Silebi, V* (Miami, USA)

P099 Dolutegravir plus rilpivirine in cART-experienced subjects: an observational cohort
Capetti, A*; Sterrantino, G; Cossu, M; De Socio, G; Di Giambenedetto, S; Celesia, B; Argenteri, B; Di Biagio, A; Orofino, G; Barbarini, G; Rizzardini, G (Milan, Italy)

P100 Switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): effects on T-cell compartment and HIV reservoirs
Merlini, E; Cazzaniga, F; Casabianca, A; Orlandi, C; Ancona, G; Cogliandro, V; Tincati, C; Bini, T; Magnani, M; d’Arminio Monforte, A; Marchetti, G (Milan, Italy)

P101 Reducing pill burden is more durable than reducing drug burden as strategy of HIV treatment simplification
Zaccarelli, M*; Lorenzini, P; Gianotti, N; Rusconi, S; Viale, P; Chirinani, A; Sighinolfi, L; Parruti, G; d’Arminio Monforte, A; Antinori, A; on behalf of the ICONA Foundation cohort (Rome, Italy)

P102 Efficacy and safety of switch to DRV/cobicistat in patients who are virologically suppressed with treatment regimens containing DRV/r
de la Fuente Moral, S*; Diaz de Santiago, A; Folguera, C; De Mendoza Fernandez, C; Angel-Moreno Maroto, A (Madrid, Spain)

P103 Confirmed efficacy and safety of dual therapy based on lamivudine plus a ritonavir-boosted protease inhibitor in the clinical setting
Fontecha-Ortega, M*; Muñoz-Mendoza, V; Gómez, C; Sánchez-Conde, M; Rodríguez, M; Vivancos, M; Casado, J (Getafe, Spain)

*Indicates presenting author.
P104  Preferred regimens and reasons for switches in HIV-positive individuals in the German HIV-HEART cohort study over 30 years of antiretroviral treatment evolution
Holzendorf, V; Esser, S*; on behalf of the HIV-HEART Study Group (Essen, Germany)

P105  Drug concentrations, adherence, patient-reported symptoms and health-related quality of life in HIV-infected, virologically controlled patients switching to maraviroc+darunavir/ritonavir or continuing the previous triple therapy: sub-studies from the randomized GUSTA trial
Rossetti, B*; Gagliardini, R; Lisi, L; Masini, M; Lamonica, S; Vignale, F; Sterratino, G; Orofino, G; Colafigl, M; Latini, A; Tosti, A; Rusconi, S; Trezzi, M; D’Avino, A; Grima, P; Mezzaroma, I; Di Biagio, A; Navarra, P; Di Giambenedetto, S; De Luca, A (Siena, Italy)

P106  A comparison between tenofovir/emtricitabine/elvitegravir/cobicistat and dolutegravir-based three-drug regimens as switch strategies for virologically controlled, HIV-infected patients
Baldin, G*; Borghetti, A; Capetti, A; Sterratino, G; Rusconi, S; Latini, A; Giacomelli, A; Cossu, M; Colafigl, M; Micale, M; Veloci, S; Lombardi, F; De Marco, R; Emiliozzi, A; De Luca, A; Di Giambenedetto, S; Maddeddu, G (Rome, Italy)

P107  Durability, metabolic impact and efficacy of switching from a PI/r- to an INI-containing regimen in a monocentric cohort of drug-experienced HIV-positive subjects
Rusconi, S*; Oreni, L; Formenti, T; Giacometti, A; Di Cristo, V; Lupo, A; Colella, E; Franzetti, M; Ridolfi, A; Galli, M (Milan, Italy)

P108  Switch to dolutegravir in HIV patients responding to a first-line antiretroviral treatment: 48 weeks results
Tau, L*; Ziv-Baran, T; Cohen-Poradosu, R; Lessno, A; Alon, D; Shasha, D; Rapaport, S; Wasserman, A; Finn, T; Katchman, E; Hassin, D; Yust, I; Brofman, T; Avidor, B; Turner, D (Tel Aviv, Israel)

P109  Antiretroviral treatment received by patients in the Spanish VACH cohort: change over time
Roca, B* (Castellon, Spain)

P110  The RAL-AGE study: benefits of switching to raltegravir-containing regimens in the older population
Pavone, P*; Giustini, N; d’Ettorre, G; Serafino, S; Schiotetra, I; Corano Scheri, G; Mezzaroma, I; Andreotti, M; Mastrangelo, A; Mastroianni, C; Vull, V (Rome, Italy)

P111  Characteristics and satisfaction survey in patients switching to darunavir/cobicistat (DRV/c)
Vivancos-Gallego, M*; Moreno, A; Quereda, C; Casado, J; Gomez Ayerbe, C; Sanchez-Conde, M; Del Campo, S; Moreno, S; Perez Elias, M (Madrid, Spain)

P112  Short-term safety and tolerability of switch of backbone antiretroviral agents to coformulated tenofovir disoproxil fumarate/emtricitabine in HIV-positive Taiwanese patients
Chang, H*; Wu, P; Zhang, J; Yang, S; Luo, Y; Liu, W; Sun, H; Hung, C; Chang, S (Taipei, Taiwan)

P113  Optimizing viral load testing to improve quality of care and client retention for PLHIVs in a HIV clinic in Northern Nigeria: impact and experiences
Nwabueze, E*; Ndulue, N; Egesimba, G; Makumbi, M; Kpamor, Z; Okechukwu, E; Kolin, J (Abuja, Nigeria)

P114  Knowing the epidemic is the best way to define diagnosis and treatment strategies to reach the 90-90-90 goals: the experience of Portugal using the ECDC HIV modelling tool
Diniz, A*; Loff, J; Cortes-Martins, H (Lisbon, Portugal)

P115  Drug retention time: a real-life Swedish nationwide cohort study on InfCareHIV 2009–2014
Häggblom, A*; Lindbäck, S; Gisslén, M; Flamholc, L; Hejdeman, B; Palmborg, A; Leval, A; Herweijer, E; Valgardsson, S; Svedhern, V (Gävle, Sweden)

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P116  Discontinuation of dolutegravir (DTG)-based regimens in clinical practice
Vivancos-Gallego, M*; Moreno, A; Perez-Elias, M; Gomez Ayerbe, C; Casado, J; Quereda, C; Sanchez-Conde, M; Serrano Villar, S; Dronda, F; Navas, E; Rodriguez, M; Moreno, S (Madrid, Spain)

P117  Dolutegravir (DTG) monotherapy treatment de-escalation in virologically controlled, pre-treated HIV patients: results from the DoluMono cohort study
Oldenbüttel, C*; Wolf, E; Ritter, A; Noe, S; Heldwein, S; Pascucci, R; Wiese, C; von Krosigk, A; Jägel-Guedes, E; Jäger, H; Balogh, A; Kögl, C; Spinner, C (Munich, Germany)

P118  Outcomes of cabotegravir (CAB) treatment in HIV-1 ART-naïve patients with chronic or acute hepatitis C virus (HCV) co-infection: data from the phase IIb programme
Thiagarajah, S*; Dorey, D; Huang, J; Roberts, G; Stancil, B; Margolis, D (London, UK)

P119  Antiretroviral treatment patterns in the USA: an analysis of real-world data
Goodwin, B*; Tran, J; White, J; Mao, J; Cao, F (Whitehouse Station, USA)

P120  Selected antiretroviral treatment option is associated with virological success: multicentre data from Poland
Parczewski, M; Leszczyzyn-Pynka, M*; Witor, A; Muller, K; Szymczak, A; Gąsiorowski, J; Bociąga-Jasik, M; Skwara, P; Grzeszczuk, A; Jablonowska, E; Wójcik-Cichy, K; Kamerys, J; Bielec, D; Stempkowska, J; Kochab, A; Bludzin, W (Szczecin, Poland)

P121  Much less treatment modification with recently approved drugs: the Austrian HIV cohort study
Rappold, M*; Rieger, A; Schmied, B; Sarcetti, M; Geil, M; Haas, B; Taylor, N; Kanatschnig, M; Leirer, G; Ledergerber, B; Zangerle, R (Innsbruck, Austria)

P122  Integrase strand transfer inhibitors in the treatment of HIV-2 infection: report of 39 patients
Sequeira, F*; Grazina, S; Alves, J; Peres, S; Borges, F; Miranda, A; Aldir, I; Mansinho, K (Penafiel, Portugal)

P123  Effect of probiotics on inflammation in the gut in HIV-infected individuals evaluated using PET/MR
Arnbjerg, C; Pedersen, K; Jespersen, S; Fischer, B; Johannesen, H; Fallentin, E; Hansen, A; Kjær, A; Trosed, M; Dam Nielsen, S* (Copenhagen, Denmark)

P124  Starting antiretroviral therapy for HIV at the first visit and early after inclusion into care: an observational study
Begovac, J; Zekan, Š*; Zidovec Lepej, S; Lukas, D (Zagreb, Croatia)

P125  Psychometric evaluation of a new individualised condition-specific quality of life questionnaire for HIV (HIVDqoL)
Romaine, J; Murray, M; Bradley, C* (London, UK)

P126  Individualized NRTI-sparing antiretroviral regimens in a real-world clinical setting maintain virologic efficacy with significant cost reduction
Arponen, S*; Gimeno-Garcia, A; Montero-Hernández, C; Esteva, L; Blasco, M; Gaspar-Garcia, E; Garcia-Navarro, M (Torrejón de Ardoz, Spain)

P127  A retrospective analysis of time to non-detectable HIV viral load in fixed dose combination anti-retroviral therapy in HIV-1-infected patients enrolled in the Mater Misericordiae University Hospital Infectious Diseases (MMUH-ID) cohort
Grant-Freemantle, M; Mallon, P; McCombe, G; Macken, A; Tinago, W; Avramovic, G; O’Halloran, J; Cotter, A; Sheehan, G; Lambert, J* (Dublin, Ireland)

*Indicates presenting author.
P128  Antiretroviral treatment changes due to treatment of hepatitis C with direct-acting antivirals in co-infected patients
Ferrero, O*; Ibarra, S; López-Azkarreta, I; de la Peña, M; López-Martínez, M; Baraia-Etxaburu, J; López de Munain, J; Cáámara, M; Zubero, Z; Muñoz, J (Bilbao, Spain)

P129  The use of protease inhibitors in patients with blips is associated with virologic failure
Sanchez-Brown, E*; Soto-Ramirez, L (Mexico City, Mexico)

P130  Baseline characteristics of the TRIUMPH and DOL-ART cohorts: use of Triumeq® (DTG/ABC/3TC) or other DTG-based ART in routine clinical care in Germany
Heuchel, T*; Postel, N; Bickel, M; Brust, J; Scholten, S; Schulz, C; Stephan, C; Bohr, U; Hillenbrand, H; Glaunsinger, T; Stoehr, A; Westermayer, B; Wigger, A; Lüftenegger, D; Walli, R (Chemnitz, Germany)

P131  Long-term use of darunavir/r QD containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV patients
De Wit, S*; Florence, E; Vandekerckhove, L; Vandercam, B; Goffard, J; Van Wijngaerden, E; Moutschen, M; Demeeister, R; Piryns, H; Thilakarathne, P (Brussels, Belgium)

P132  Assessment of the results at 96 weeks of a multicentric Portuguese cohort of patients treated with emtricitabine/tenofovir/rilpivirine
Almeida, F; Sequeira, F; Casella, M; Mota, M; Serrão, R; Mesquita, M; Goes, A; Teixeira, T; Piñeiro, C* (Porto, Portugal)

P133  The DOL-ART cohort: providing evidence from real-world data – use of dolutegravir-based regimens in routine clinical care in Germany
Postel, N*; Mueller, M; Wyen, C; Brust, J; Stoehr, A; Glaunsinger, T; Scholten, S; Rausch, M; Westermayer, B; Herrmann, M; Walli, R (Munich, Germany)

P134  First Canadian HIV+/HIV+ kidney transplantation and first results of the prospective cohort of solid organ transplantation for HIV individuals of Centre Hospitalier de l’Université de Montréal
Ambaraghassi, G*; Cardinal, H; Corsilli, D; Fortin, C; Fortin, M; Malaise, J; Martel-Laferrière, V; Pâquet, M; Rouleau, D (Montréal, Canada)

P135  Why do HIV/AIDS patients fail? Incidence, causes, demographic, immunologic and clinical characteristics of HIV patients who fail to achieve complete virologic suppression
Elbirt, D*; Inberg, Y; Mahlab-Guri, K; Asher, I; Bezalel-Rosenberg, S; Burke, M; Sthoezer, Z (Rehovot, Israel)

P136  Hepatic safety during treatment with darunavir-based regimens in an Italian observational study
Antinori, A; Gori, A; Cauda, R; Orofino, G; Di Sora, F; Grossi, P; Mineo, M; Airoldi, G; Mancusi, D*; Termini, R (Cologno Monzese, Italy)

P137  Long-term use of darunavir/r QD monotherapy in daily practice: retrospective observational cohort data of 111 HIV patients in Belgium
De Wit, S*; Florence, E; Vandekerckhove, L; Vandercam, B; Goffard, J; Van Wijngaerden, E; Moutschen, M; Demeeester, R; Piryns, H; Thilakarathne, P (Brussels, Belgium)

P138  Development of a contemporary symptom diary for patients with HIV
Markowitz, J*; Knoble, N; Arnould, B; Wu, A (Boston, USA)

P139  A moderated mediation model of HIV-related stigma, depression and social support on health-related quality of life among incarcerated Malaysian men with HIV and opioid dependence
Shrestha, R*; Copenhaver, M; Altice, F (Farmington, USA)

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P140  The DRIVER study: asymptomatic STI systematic screening versus targeted screening according to STI risk factors in a cohort of outpatients HIV-infected MSM seen in France: phase 1 results
Fouere, S; Dimi, S; Timsit, J; Lalanne, C; Chassany, O; Duracinsky, M; Farfour, E; Majerholc, C; Zucman, D* (Suresnes, France)

P141  Metabolic safety during treatment with darunavir-based regimens in an Italian observational study
Antinori, A; Di Perri, G; Meraviglia, P; Angioni, G; Chirianni, A; Sterrantino, G; Quirino, T; Airoldi, G; Mancusi, D; Termini, R* (Cologno Monzese, Italy)

Opportunistic Infections

P142  Low rifampicin and isoniazid concentrations are associated with delayed sputum conversion in HIV-positive patients co-infected with tuberculosis in Uganda
Sekaggya, C*; Ledergerber, B; von Braun, A; Lamorde, M; Buzibye, A; Eberhard, N; Scherrer, A; Nakijoba, R; Müller, D; Henning, L; Gutteck, U; Corti, N; Musaazi, J; Kamya, M; Castelnuovo, B; Kambugu, A; Fehr, J (Kampala, Uganda)

P143  Isoniazid preventive therapy is highly cost-effective among TB/HIV co-infected patients in Uganda
Wiltshire, C*; Kuznik, A; Lamorde, M (Kampala, Uganda)

P144  Predicting the in-hospital mortality in tuberculous meningitis
Jipa, R*; Manea, E; Olaru, I; Merisor, S; Niculae, C; Hristea, A (Bucharest, Romania)

P145  Tuberculosis infection in HIV patients in a Portuguese population
Maio, A; Coutinho, D; Nunes, S; Velez, J*; Freitas, F; Oliveira, C (Aveiro, Portugal)

P147  Use of dolutegravir in combination with rifampicin-based TB therapy in HIV/TB co-infected patients: real-world experience from Leeds, UK
Cevik, M*; Vincent, R; McGann, H (Edinburgh, UK)

P148  The practice and value of interferon gamma release assay testing for latent tuberculosis infection in people living with HIV: a retrospective review of patients at Leeds Teaching Hospitals Trust
Baggott, A*; Cevik, M; McGann, H (Leeds, UK)

P149  The global burden of AIDS in tuberculosis-infected patients and related financial aspects
Sargazi, A*; Sepehri, Z; Nadakkavukaran Jim, P; Sargazi, A (Zabol, Iran)

P150  Incidence and survival in HIV-infected patients with central nervous system opportunistic infections in the cART era: a 10-year Romanian single-center experience
Oprea, C*; Ianache, I; Popa, I; Ene, L; Radoi, R; Tardei, G; Ungureanu, E; Ersoiu, S; Ceausu, E; Calistru, P (Bucharest, Romania)

P151  In spite of international guidelines, vaccine coverage of HIV-infected patients remains low
Gagneux-Brunon, A*; Frésard, A; Detoc, M; Charrière, E; Ronat, V; Lucht, F; Botelho-Nevers, E (Saint-Etienne, France)

P152  Does syphilis impact on HIV infection when both diagnoses are concomitant?
Palacios, R*; González-Domenech, C; Antequera, I; Ruiz-Morales, J; Nuño, E; Clavijo, E; Márquez, M; Santos, J (Málaga, Spain)

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

Co-morbidities and Complications of Disease and/or Treatment

P153  Health-related costs in chronic HIV infection: a case-control study versus general population using a claims-based approach in Germany
Wolf, E*; Christensen, S (Munich, Germany)

P154  Ageing and the evolution of co-morbidities among HIV patients in the EuroSIDA cohort
Lopes, S*; Kirk, O; Lundgren, J; Laut, K; Edwards, S; Duvivier, C; Stephan, C; Sambatakou, H; Maciejewska, K; Aragão, F; Mocroft, A (London, UK)

P155  Future challenges for clinical care of an ageing population infected with HIV: a ‘geriatric HIV’ modelling study
De Francesco, D*; Malagoli, A; Theou, O; Zona, S; Carli, F; Dolci, G; Mussini, C; Kirkland, S; Mussi, C; Cesari, M; Rockwood, K; Guaraldi, G (London, UK)

P156  Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study
Smit, M*; Cassidy, R; Cozzi-Lepri, A; Girardi, E; Mammine, A; Antinori, A; Angarano, G; Bai, F; Rusconi, S; Magnani, G; d’Arminio Monforte, A; Hallett, T (London, UK)

P157  Quantifying the future clinical burden of an ageing HIV-positive population in the USA: a mathematical modelling study
Smit, M*; Cassidy, R; Hallett, T (London, UK)

P158  Silver champions from the GEPPPO cohort: a case control study of people between 65 and 75 years old and above 75 years of age addressing co-morbidities, multimorbidity and polypharmacy
Guaraldi, G*; Malagoli, A; Dolci, G; Calcagno, A; Mussi, C; Celesia, B; Carli, F; Piconi, S; De Socio, G; Cattelan, A; Orofino, G; Riva, A; Morena, V; Focà, E; Nozza, S; Bugliosi, E; Di Perri, G (Modena, Italy)

P159  Co-morbidity in chronic HIV infection: a case-control study in Germany using health insurance claims data
Christensen, S*; Wolf, E (Munich, Germany)

P160  Burden and determinants of frailty in a cohort of asymptomatic HIV ART-suppressed subjects without known co-morbidities
Vita, S*; Lichtner, M; Rossi, R; Pozzetto, I; Tosato, C; Marocco, R; Zuccalà, P; Mascia, C; Campagna, M; d’Ettorre, G; Turniniani, O; Falasca, F; Ajasssa, C; Mastroianni, C; Vincenzo, V (Rome, Italy)

P161  Current models of care for the management of HIV patients with co-morbidities in England: a survey
Youssef, E*; Cooper, V; Nixon, E; Vera, J; Fisher, M; Wright, J (Brighton, UK)

P162  The HIV patient profile in 2013 and 2003: results from the Greek AMACS cohort
Pantazis, N*; Chini, M; Antoniadou, A; Sambatakou, H; Skoutelis, A; Gargalianos, P; Papanizos, V; Gogos, C; Chrysos, G; Psychogiu, M; Sipsas, N; Katsarou, O; Penklis, P; Touloumi, G (Athens, Greece)

P163  Antiretroviral therapy in Italian geriatric patients living with HIV/AIDS: analysis of GEPPPO cohort
Nozza, S*; Malagoli, A; Dolci, G; Calcagno, A; Mussi, C; Celesia, B; Carli, F; Piconi, S; De Socio, G; Cattelan, A; Orofino, G; Riva, A; Morena, V; Focà, E; Bugliosi, E; Di Perri, G; Guaraldi, G (Milan, Italy)

P164  CD4/CD8 ratio matters to age-related health outcomes in HIV-infected patients with co-morbidities, frailty and disability
Menozza, M*; Domingues da Silva, A; Malagoli, A; Dolci, G; Santoro, A; Carli, F; Mussini, C; Guaraldi, G (Modena, Italy)

*Indicates presenting author.
**P165** Mortality rates and excess mortality among HIV-positive persons according to age in Spain, 2004–2014
Alejos, B*; Hernandez, V; Viciana, P; Montero, M; Berenguer, J; Rivero, M; Asensi, V; Garcia-Fraile, L; Gutierrez, F; Moreno, S; CoRIS cohort (Madrid, Spain)

**P166** Changes in the prevalence of cardiovascular, renal and bone co-morbidities and related risk factors in HIV-infected patients in the Spanish VACH cohort: a cross-sectional study in 2010 and 2014
Teira, R*; Suarez-Lozano, I; Galindo, M; Montero, M; Geijo, P; Muñoz-Sanz, A; Martinez, E; Domingo, P; Lozano, F; Viciana, P; de la Fuente, B; Roca, B; Estrada, V; Muñoz-Sanchez, P; Vach, S (Torrelavega, Spain)

**P167** Epidemiologic ‘snapshot’ of the HIV-positive population in Belgium, 2014–2016
Callens, S; De Wit, S; Wyndham-Thomas, C; Goffard, J; Moutschen, M; van den Bulcke, C; Fombellida, K; del Forge, M; Razavi, H; Gunter, J* (Lafayette, USA)

**P168** From HIV diagnosis to viral suppression in a cohort of older patients
Kundro, M*; Viloria, G; Toibaro, J; Losso, M (Buenos Aires, Argentina)

**P169** The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort
McGinty, T*; Cotter, A; Sabin, C; Lambert, J; Sheehan, G; Macken, A; Kavanagh, E; Compston, J; Mallon, P (Dublin, Ireland)

**P170** Bone outcomes with EFV + TDF/FTC versus other TDF-containing antiretroviral regimens among HIV-infected veterans: a US national study
LaFleur, J; Bress, A; Myers, J*; Rosenblatt, L; Crook, J; Nyman, H; Bedimo, R; Tebas, P; Esker, S (Salt Lake City, USA)

**P171** Prevalence and risk factors of vertebral fractures in patients on antiretroviral treatment
Weiser-Smike, A; Mata-Marin, J*; Liña-Amador, M; Espinoza-Armenta, B; Gil-Avila, A; Gaytán-Martinez, J (Mexico City, Mexico)

**P172** Quantifying fracture risk in clinical practice: treatment for osteoporosis should be considered in approximately one out of four HIV+ individuals ≥40 years
Siakalis, G*; Protopapas, K; Makras, P; Katsarolis, I; Kavatha, D; Papadopoulos, A; Antoniadou, A (Athens, Greece)

**P173** Bone deficits in HIV mono-infected and HIV/HCV co-infected individuals belonging to the native Sicilian and migrant/refugee populations, demonstrated by DEXA scanning
Lo Re, G; Di Carlo, P*; Gambino, A; Serra, N; Colomba, C; Lo Casto, A; Guglielmi, G; Cascio, A; La Galla, R (Palermo, Italy)

**P174** Cardiovascular events: a thing of the past? A real-life assessment in an inner-city Toronto clinic
Crouzat, F*; Varriano, B; Sandler, I; Smith, G; Steinberg, S; Kovacs, C; Fletcher, D; Knox, D; Markley, B; Chang, B; Tilley, D; Ascai, M; Sharma, M; Loufty, M (Toronto, Canada)

**P175** Risk of cardiovascular disease events with atazanavir-based antiretroviral treatment regimens among HIV-infected veterans: a US national study
LaFleur, J; Bress, A; Rosenblatt, L; Crook, J; Sax, P; Myers, J; Ritchings, C* (Salt Lake City, USA)

**P176** A reappraisal with meta-analysis of abacavir use and cardiovascular disease events
Cruciani, M*; Parisi, S (Verona, Italy)
P177  Awareness and management of elevated blood pressure among HIV-infected adults receiving antiretroviral therapy in urban Zambia
Bauer, S*; Zyanbo, Z; ma Mwanza, M; Chilengi, R; Davies, MA; Egger, M; Furrer, H; Vinikoor, M; Wandeler, G (Bern, Switzerland)

P178  Reduction of immune activation in HIV-infected patients after introducing pitavastatin
Bernal Morell, E*; Martínez, M; Bravo, J; Vera, F; Martínez, O; Galera, C; Muñoz, A; Marín, I; Alcaraz, A; Cano, A; Valero, S; Gomez Verdu, J; Torres, A; Minguela, A (Murcia, Spain)

P179  Extensive vascular phenotyping – for the detection of subclinical atheromatosis, arteriosclerosis and arterial hypertrophy – and its association with international cardiovascular prediction scores in HIV-infected individuals: a single-center study
Psichogiou, M*; Arida, K; Papadopoulou, M; Papaioannou, T; Lazarini, A; Konstantonis, G; Petrikkos, P; Daikos, G; Kitas, G; Stikakis, P; Protogerou, A (Athens, Greece)

P180  Initiation of antiretroviral therapy restores endothelial cell function in HIV-infected individuals
Echeverría, P*; Gómez-Mora, E; Roura, S; Bayés-Genis, A; Bonjoch, A; Puig, J; Pérez-Alvarez, N; Clotet Sala, B; Blanco, J; Negredo, E (Barcelona, Spain)

P181  Cardiovascular risk factors and use of lipid-lowering therapy in a cohort of HIV-positive patients with high cardiovascular risk
Denman, J*; Manavi, K (Birmingham, UK)

P182  Prevalence of cardiovascular diseases in West African HIV-infected adults receiving HAART
Ello, N*; Mossou, C; Coffie, P; Kouakou, A; Iklo, C; Anzoua-Kacou, J; Eholie, S (Abidjan, Ivory Coast)

P183  Premature cerebral atherosclerosis in HIV-infected individuals in Lisbon: a carotid ultrasound and transcranial Doppler study
Pais de Lacerda, A*; Melo, M; Coelho, P; Baptista, P; Soares, F; Caldeira, L; Valadas, E; Oliveira, V (Lisbon, Portugal)

P184  CVD risk assessment using various tools in an HIV cohort in Greece
Zouzia, E; Kakalou, E*; Papastamopoulos, V; Kakavas, T; Dimas, D; Rosenberg, T; Skoutelis, A (Athens, Greece)

P185  Myocardial inflammatory changes before and after ART in HIV-infected patients with advanced disease
Piñeirua Menendez, A*; Flores Miranda, R; Sánchez Nava, D; Ortega Pérez, R; Belaunzarán Zamudio, F; Pérez Patrigeon, S; Cardenas Ochoa, A; Oseguera Moguel, J; Galindo Uribe, J; Orihuela Sandovai, C; Vásquez Ortíz, Z; Vásquez Lamadrid, J; Morelos Guzmán, M; Rosales Uvera, S; Crabtree Ramírez, B; Sierra Madero, J (Mexico City, Mexico)

P186  TDF/FTC/RPV + atorvastatin as co-morbidity-driven cART
Maggiolo, F*; Di Filippo, E; Comi, L; Callegaro, A; Valenti, D; Gregis, G (Bergamo, Italy)

P187  Lipid profile in HIV patients with long-term ART: darunavir versus raltegravir versus rilpivirine
Branco Ascencão, B*; Casella, I; Gonçalves, C; Luís, N; Goes, A; Sá, J; Brito, A; Poças, J (Setubal, Portugal)

P188  Cardiovascular disease risk scores comparison in Serbian HIV-infected patients
Dimitrijevic, B*; Jevtic, D; Soldatovic, I; Ranin, J; Salemovic, D; Kusic, J; Dragovic, G (Belgrade, Serbia and Montenegro)
POSTER PRESENTATIONS (continued)

P189  The extent of B-cell activation and dysfunction preceding lymphoma development
Shepherd, L; Borges, A; Harvey, R; Bower, M; Grulich, A; Silverberg, M; Weber, J; Ristola, M; Viard, J; Bogner, J; Gargalianos-Kakolyri, P; Mussini, C; Mansinho, K; Yust, I; Calmy, A; Paduta, D; Jalil, D; Smiatacz, T; Radoi, R; Tomazic, J; Plomgaard, P; Frikke Schmidt, R; Lundgren, J; Mocroft, A; EuroSIDA in EuroCOORD (Copenhagen, Denmark)

P190  Survival in HIV-1-infected individuals with diagnosis of lymphoma compared to general population: data from the ICONA Foundation cohort
Cingolani, A; Cozzi Leprini, A; Teofilí, L; Galli, L; Mazzotta, V; Baldin, G; Hohaus, S; Bandera, A; Alba, L; Galizzi, N; Castagna, A; d’Arminio Monforte, A; Antinori, A; on behalf of the ICONA Foundation cohort (Rome, Italy)

P191  Cervical and breast cancer screening practices among women living with HIV
Salters, K; Ye, M; Burchell, A; Pick, N; Smith, D; Jabbari, S; Hull, M; Shoveller, J; Montaner, J; Hogg, R (Burnaby, Canada)

P192  Immune suppression at cART initiation is associated with cancer development in women living with HIV/AIDS
Salters, K; Ye, M; Pick, N; Smith, D; Wiseman, S; Jabbari, S; Hull, M; Shoveller, J; Montaner, J; Hogg, R (Burnaby, Canada)

P193  High rate of the progression of low squamous intraepithelial lesion (LSIL) to high squamous intraepithelial lesion (HSIL) in a cohort of HIV MSM in “the modern antiretroviral era”
Hidalgo-Tenorio, C; Gil Anguita, C; Ramirez Taboada, J; Lopez Ruz, M; Omar Momamed Balghata, M; Javier, R; Esquivias, J; Gutierrez, M; Pasquau, J (Granada, Spain)

P194  Relapse of HIV-associated multicentric Castleman’s disease following rituximab-based immunotherapy
Dalla Pria, A; Roe, J; Bracchi, M; Pagani, N; McFaul, K; Forni, J; Merchant, S; Samani, A; Byrne, R; Nelson, M; Bower, M (London, UK)

P195  Incidence of cancer in a cohort of HIV-positive patients on virologically suppressive antiretroviral therapy in Western India: a resource-limited setting perspective
Dravid, A; Kulkarni, P; Saraf, C; Kulkarni, M; Kore, S; Rathod, N (Pune, India)

P196  Self-administered treatment with imiquimod 5% cream for intra-anal HSIL (AIN2/3) in HIV-positive patients: efficacy, safety and a comfortable option
Hidalgo-Tenorio, C; Gil Anguita, C; Ramirez Taboada, J; De Jesus, S; Esquivias, J; Alvarez, M; Gutierrez, M; Lopez Ruz, M; Javier, R; Pasquau, J (Granada, Spain)

P197  Investigating barriers in HIV-testing oncology patients: the IBITOP study phase II
Nguyen-Ngoc, T; Cavassini, M; Marz, L; Zimmermann, S; Peters, S; Darling, K (Lausanne, Switzerland)

P198  A descriptive study of cancer incidence in a cohort of HIV-infected patients followed since 1986
Montejano, R; Arribas, J; Bernardino, J; Martin-Carbonero, L; Montes, M; Moreno, V; Perez Valero, I; Gonzalez Garcia, J; Valencia, E (Madrid, Spain)

P199  Human papilloma virus and HIV
Popova, A; Kravtchenko, A; Deulina, M; Shipulina, O (Moscow, Russian Federation)

P200  Glucose metabolism disorders, HIV and antiretroviral therapy among Tanzanian adults
Maganga, E; Smart, L; Kalluvya, S; Katarahi, J; Saleh, A; Obeid, L; Downs, J; Fitzgerald, D; Peck, R (Doha, Qatar)

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P201 Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2013
Wu, P*; Yang, S; Lou, Y; Zhang, J; Chang, H; Sun, H; Sheng, W; Hsieh, S; Hung, C (Taipei, Taiwan)

P202 Comparison of risk tools to estimate type 2 diabetes risk in an urban HIV cohort
Mok, J*; Goff, L; Peters, B; Duncan, A (London, UK)

P203 Lipodystrophy as cause of metabolic syndrome: a contribution of antiretroviral drugs to increased cardiovascular risk
Muñoz-Mendoza, V*; Fontecha-Ortega, M; Gómez Ayerbe, C; Vivancos Gallego, M; Sánchez Conde, M; Casado Osorio, J (Teruel, Spain)

P204 Normalisation of undernutrition following initiation of HAART is not associated with future diabetes risk
Mok, J*; Goff, L; Peters, B; Duncan, A (London, UK)

P205 Hepatic steatosis is highly prevalent in HIV and significantly associated with diabetes risk
Mok, J*; Goff, L; Peters, B; Duncan, A (London, UK)

P206 HIV-positive inflammatory activity monitoring correlated to insulin resistance: HIRE study
Soares Medeiros, M*; Pires Moreira, H; Veras Da Ponte, D; dos Santos Araujo, A; Pereira de Brito Neves, A; Santos Souza, R; Lucena Chaves, H; Feitosa de Queiroga, M; Ximenes Paula, V; Antonio Gomes Arruda, E (Fortaleza, Brazil)

P207 A cross-sectional study of co-morbidities in HIV-infected patients receiving cART in Taiwan: a nationwide surveillance
Yang, C*; Wang, H; Chou, T; Chang, C (New Taipei City, Taiwan)

P208 Tryptophan metabolism and its relationship with central nervous system toxicity in subjects switching from efavirenz to dolutegravir
Keegan, M*; Winston, A; Higgs, C; Fuchs, D; Boasso, A; Nelson, M (London, UK)

P209 Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity
Bracchi, M; Pagani, N*; Clarke, A; Adams, T; Waters, L; Bolton, M; Winston, A; Mora-Peris, B; Dickinson, L; Boffito, M; Nelson, M (London, UK)

P210 Psychiatric adverse events from the DTG ART-naïve phase 3 clinical trials
Quercia, R*; Roberts, J; Murungi, A; Curtis, L; Payvandy, N; Koteff, J; Aboud, M (Brentford, UK)

P211 Prevalence of undiagnosed neurocognitive impairment in HIV-infected adults taking efavirenz on a long-term basis with undetectable or low HIV RNA compared with protease inhibitors
Marques, N*; Fernandes, C; Tejo, S; Rosa, A; Nogueira, M; Rocha, S; Trêpa, J; Saraiva da Cunha, J (Almada, Portugal)

P212 Adverse events and discontinuation of dolutegravir-based therapy in naïve and experienced HIV patients: tertiary HIV centre experience
Fernandez, C*; Michie, K; Thomson-Glover, R; Chaponda, M; Ratcliffe, L (Liverpool, UK)

P213 Cerebrospinal fluid and plasma biomarkers in patients with HIV-associated neurocognitive disorders
Trunfio, M*; Vai, D; Romito, A; Atzori, C; Imperiale, D; Audagnotto, S; Montrucchio, C; Scabini, S; Cardellino, C; Pirriatore, V; Di Perri, G; Bonora, S; Calcagno, A (Turin, Italy)

P214 Incidence of CSF HIV escape in patients on virologically suppressive second-line protease inhibitor-based ART in Pune, Western India
Dravid, A*; Saraf, C; Kulkarni, M; Kore, S; Rathod, N; Mahajan, U (Pune, India)

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P215 Monitoring of 8-hydroxy-efavirenz concentrations for management of mood changes
Grilo, N; Correia, M; Sequeira, C; Harjivan, S; Caixas, U*; Diogo, L; Marques, M; Monteiro, E; Antunes, A; Pereira, S (Lisbon, Portugal)

P216 The predictive role of cerebrospinal fluid (CSF)/plasma immune activation and neuronal injury biomarkers for HIV-associated neurocognitive disorders (HAND) diagnosis: a cross-sectional study
Pinnetti, C*; Fedele, V; Balestra, P; Carta, S; Lorenzini, P; Ammassari, A; Bordoni, V; Alba, L; Mazzotta, V; Grisetti, S; Martini, F; Ceccherini-Silberstein, F; Perno, C; Antinori, A (Rome, Italy)

P217 Neuro+3 study: cognitive evolution in HAND after 96 weeks of treatment intensification with higher CNS penetration score
Force, G*; De Truchis, P; Marigot-Outtandy, D; Le Du, D; Troisvallets, D; Blum, L; Alf-Mohand, H; Ghout, I; Hahn, V; Defenèrie, H; Darchy, N; Lecornu, C; Brefort, S; Larroze, M; Sauvage, M; Delaugerre, C; Néré, M; Mahjoub, N; Peytavin, G (Levallois, France)

P218 Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
Jose, S*; Nelson, M; Phillips, A; Chadwick, D; Trevelion, R; Jones, R; Williams, D; Hamzah, L; Sabin, C; Post, F (London, UK)

P219 Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV co-infected individuals in Sub-Saharan Africa: results from the HEPIK cohort
Villa, G*; Phillips, R; Smith, C; Stockdale, A; Beloukas, A; Appiah, L; Chadwick, D; Ruggiero, A; Sarfo, F; Post, F; Geretti, A (Liverpool, UK)

P220 Factors associated with decreased estimated glomerular filtration rate (eGFR) among HIV-1 positive persons in methadone program: data from Warsaw HIV Outpatient Clinic
Matłosz, B*; Pietraszkiewicz, E; Firlag-Burkacka, E; Grycner, E; Horban, A; Kowalska, J (Warsaw, Poland)

P221 Kidney tubular dysfunction and decline in renal function in HIV-infected Chinese people receiving tenofovir disoproxil fumarate
Lui, C*; Chan, P; Cheung, C; Lee, M; Nattalin, C; Chan, K; Wong, N; Lee, S (Hong Kong, Hong Kong)

P222 TDF, ATV/r and other ARV: renal safety in a resource-limiting country
Berald de Magalhaes, P*; Silva Penteado, S; Collodetto Soares, M; Claro Amaral, D; Mello Mazepa, M; Kato, P; Gomes da Silva, M (Curitiba, Brazil)

P223 Kidney transplant in HIV-positive population: outcomes and therapeutic perspectives in a 10-year experience
Chirico, C*; Izzo, I; Casari, S; Bossini, N; Brianese, N; Forleo, M; Focà, E; Sandrini, S; Castelli, F (Brescia, Italy)

P224 Renal function and chronic kidney disease prognosis through the lens of co-morbidities in people living with HIV infection: an association hard to escape
Kalkounou, I*; Retsas, T; Kourkounti, S; Katsarolis, I; Paparizos, V (Athens, Greece)

P225 Different classifications of chronic kidney disease (CKD) in HIV-infected patients result in large discrepancies in CKD prevalence in this population
Gagneux-Brunon, A*; Frésard, A; Guglielminotti, C; Cazorla, C; Lucht, F; Botelho-Nevers, E (Saint-Etienne, France)

P226 Urinary products of N-acetyltransferase 8 as indicators of kidney disease progression in HIV infection
Dias, C; Diogo, L; Trigo, D*; Campos, P; Lemos, A; Morello, J; Pacheco, P; Monteiro, E; Soto, K; Pereira, S (Lisbon, Portugal)

* Indicates presenting author.
POSTER PRESENTATIONS (continued)

P227  Nephrotic range proteinuria in a patient with HIV infection and a history of intravenous drug abuse: case report and review of the literature
Tsilika, M*; Kavatha, D; Protopapas, K; Siakallis, G; Papadopoulos, A; Antoniadou, A (Athens, Greece)

P228  Tolerability of integrase inhibitors in a real-life setting
Padilla, M; Rojas, J; Gonzalez-Cordon, A; Blanco, J; Blanch, J; Lonca, M; Torres, B; Martinez-Rebollar, M; Laguno, M; Tricas, A; Rodriguez, A; Mallolas, J; Gatell, J; de Lazzari, E; Peñañuelo, J; Martinez, E* (Barcelona, Spain)

P229  Erythrocyte inosine triphosphatase activity: a potential biomarker for adverse events during combination antiretroviral treatment for HIV
Peltenburg, C*; Bierau, J; Bakker, J; Schippers, J; Lowe, S; Paulussen, A; van den Bosch, B; Leers, M; Hansen, B; Verbon, A (Rotterdam, The Netherlands)

P230  Dolutegravir tolerability in clinical practice: results from the SCOLTA cohort
Madeddu, G*; Ricci, E; Guiminietti, R; Paola, B; Squillace, N; De Socio, G; Menzaghi, B; Giancarlo, O; Molteni, C; Rusconi, S; Celesia, B; Bellacosa, C; Di Biagio, A; Pellicanò, G; Martinelli, C; Carenzi, L; Valsecchi, L; Calza, L; Falasca, K; Vichi, F; Penco, G; Bontanfi, P (Sassari, Italy)

P231  Prevalence, spectrum, predictors and screening of clinically significant chronic liver disease associated with didanosine use in HIV-infected individuals
Millard, J*; Gilleece, Y; Verma, S (London, UK)

P232  Neurocognitive performance and psychological symptoms improve in HIV-positive patients switching from an efavirenz (EFV)- to a rilpivirine (RPV)-based cART
Pinnetti, C*; Ricottini, M; Balestra, P; Lorenzini, P; Libertone, R; Mazzotta, V; Plazzi, M; Bellagamba, R; Zaccarelli, M; Antinori, A; Ammassari, A (Rome, Italy)

P233  First-line ARV treatment characteristics among HIV-infected patients with and without co-morbidities
Prajapati, G*; Zhang, D; Goodwin, B (Rahway, USA)

P234  Adverse events occurring after introduction of EVG/COBI/FTC/TDF: data from the Surveillance COhort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) cohort
Squillace, N*; Bonfanti, P; Ricci, E; Calza, L; Celesia, B; Martinelli, C; Vichi, F; Cordier, L; Carenzi, L; Franzetti, M; De Socio, G; Peruzzo, F; Orofino, G; Bellacosa, C; Di Biagio, A; Gori, A; Girino, T (Monza, Italy)

P235  Prevalence of smoking and nicotine dependence in HIV patients, the project STOPS HIV from Italy
De Socio, G*; Ricci, E; Dell’Omo, M; Maggi, P; Schiaroli, E; Santoro, C; Squillace, N; Angelis, G; Patacca, A; Tiri, B; Abeli, C; Madeddu, G; Magnè, F; Molteni, C; Vichi, F; Francisci, D; Baldelli, F (Perugia, Italy)

P236  Soft modelling of health-related quality of life specific to HIV in relation to anxiety, depression, personality traits and precariousness
Duracinsky, M*; Lalanne, C; Piroth, L; Aboromman, M; Weiss, L; Rami, A; Chassany, O (Paris, France)

P237  Prevalence and predictors of HPV infection at oral cavity and anal site: findings in an Italian anal cancer screening program for HIV-positive males
Garbuglia, A; Piselli, P; Gentile, M; Del Nonno, F; Sias, C; Lapa, D; Libertone, R; Lupi, F; Baiocchini, A; Capobianchi, M; Ammassari, A* (Rome, Italy)

P238  Prevalence and presentation of syphilitic hepatitis in HIV-infected patients
Raycraft, T*; Alimohammadi, A; Singh, A; Kiani, G; Shahi, R; Hakobyany, S; Conway, B (Vancouver, Canada)

*Indicates presenting author.
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P239</td>
<td>The impact of engagement in care on the life expectancy of people living with HIV</td>
<td>Jose, S*; May, M; Sabin, C (London, UK)</td>
</tr>
<tr>
<td>P240</td>
<td>Long sleep and longer naps are associated with severity of HIV disease</td>
<td>Faraut, B; Malmartel, A; Ghosn, J; Duracinsky, M*; Léger, D; Grabar, S; Viard, J (Paris, France)</td>
</tr>
<tr>
<td>P241</td>
<td>High rates of alcohol and illicit drug consumption among HIV-infected patients attended in Spain</td>
<td>Gonzalez-Baeza, A*; Hontañon-Antoñana, V; Caceres, G; Montes, J; Perez-Valero, I (Madrid, Spain)</td>
</tr>
<tr>
<td>P242</td>
<td>Common co-morbidities found in a population of clinically stable HIV-infected patients on chronic antiretroviral therapy in five ambulatory clinics in Lima–Callao, Peru</td>
<td>Hidalgo, J*; Flores, A; Agurto, C; Pinedo, Y; Gutierrez, R; Rodriguez, L; Ayarza, R (Lima, Peru)</td>
</tr>
<tr>
<td>P243</td>
<td>Quality of life in an Italian cohort of women living with HIV: preliminary results from IANUA study (Investigation on Antiretroviral Therapy)</td>
<td>Venturini, A; Cenderello, G; Giannini, B; Montefiori, M; Di Biagio, A; Penco, G*; Mazzarello, G; Orcamo, P; Merlano, C; Setti, M; Giacomini, M; Viscoli, C; Cassola, G (Genoa, Italy)</td>
</tr>
<tr>
<td>P244</td>
<td>Seasonal variations in vitamin D levels in HIV-infected patients: when to test for hypovitaminosis?</td>
<td>Noe, S; Heldwein, S; Pascucci, R; Oldenbuettel, C; von Krosigk, A; Wiese, C; Jaegel-Guedes, E; Jäger, H; Mayer, W; Wolf, E; Spinner, C* (Munich, Germany)</td>
</tr>
<tr>
<td>P245</td>
<td>Utilizing US prescription and claims data to better understand treatment dynamics of HIV/HCV co-infection patients in the second generation DAA era</td>
<td>Denarie, M; Gubernick, S*; Panchatcharam, N; Gao, S; O’Neil, S; Arluck, J (Plymouth Meeting, USA)</td>
</tr>
<tr>
<td>P246</td>
<td>Comparison of early serologic response of early syphilis to treatment with a single-dose benzathine penicillin G between HIV-positive and HIV-negative patients: a cohort study</td>
<td>Su, Y; Chang, L; Liu, W; Wu, C; Yang, C*; Hung, C (New Taipei City, Taiwan)</td>
</tr>
<tr>
<td>P247</td>
<td>Cognitive and emotional functioning in HIV-infected MSM treated with effective antiretroviral therapy</td>
<td>Szymańska, B*; Łojek, E; Gawron, N; Cholewińska, G; Firlag-Burcka, E; Horban, A; Borstein, R (Warsaw, Poland)</td>
</tr>
</tbody>
</table>

**Viral Hepatitis**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P248</td>
<td>TURQUOISE-I part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection</td>
<td>Rockstroh, J; Orkin, C*; Viani, R; Wyles, D; Luetkemeyer, A; Lazzarin, A; Soto-Malave, R; Nelson, M; Bhagani, S; Klinker, H; Rizzardini, G; Girard, P; Shulman, N; Hu, Y; Fredrick, L; Trinh, R; Gane, E (London, UK)</td>
</tr>
<tr>
<td>P249</td>
<td>New findings in HCV genotype distribution in selected West European, Russian and Israeli regions</td>
<td>Kartashev, V; Doering, M; Nieto, L; Coletta, E; Heger, E; Neumann-Fraune, M; Kaiser, R; Sierra, S* (Cologne, Germany)</td>
</tr>
<tr>
<td>P250</td>
<td>Progression of liver fibrosis among HIV-infected patients under suppressive antiretroviral therapy: role of untreated HCV and other unrelated factors in the ICONA Foundation study cohort</td>
<td>Lapadula, G*; Soria, A; Lorenzini, P; De Luca, A; Puoti, M; Antinori, A; Mastroianni, C; Cassola, G; Bonora, S; Santoro, M; Gori, A; d’Arminio Monforte, A (Monza, Italy)</td>
</tr>
</tbody>
</table>

*Indicates presenting author.
P251  Hepatitis C can be cured for less than $100 per person: analysis of drug exports from India
   Hill, A*; Gotham, D; Barber, M; Pozniak, A; Fortunak, J (London, UK)

P252  Hepatitis C virus screening project of patients on current anti-HCV therapy
   Knops, E; Kalaghaneti, P; Neumann-Fraune, M; Heger, E; Schütter, E; Timm, J; Walker, A; Lengauer, T;
   Keitel, V; Goeseer, T; Esser, S; von Hahn, T; Pauser, I; Quirishi, N; Roemer, K; Scholten, S; Daeumer, M;
   Obermeier, M; Kaiser, R; Sierra, S* (Cologne, Germany)

P253  Are HIV/HCV co-infected patients more likely to experience multiple lines of ART than
   HIV mono-infected patients? Results from the ICONA Foundation study
   Marchetti, G*; Bruno, R; Shanyinde, M; Mussini, C; Caramello, P; Zaccarelli, M; Andreoni, M;
   d'Arminio Monforte, A; Cozzi-Leprini, A (Milan, Italy)

P254  Rapid decline of anti-HCV antibodies following treatment of incident HCV infection in HIV-
   infected MSM in the Swiss HIV Cohort Study (SHCS)
   Aebi-Popp, K*; Wandeler, G; Salazar-Vizcaya, L; Fehr, J; Stoeckle, M; Hoffmann, M; Suter-Riiker, F;
   Luethi, A; Calmy, A; Cavassini, M; Bamasconi, E; Rauch, A (Bern, Switzerland)

P255  Effectiveness of hepatitis A vaccination in HIV-positive men who have sex with men during
   an ongoing hepatitis A outbreak in Taiwan
   Lin, K*; Wu, P; Liu, W; Sun, H; Lo, Y; Hsieh, S; Sheng, W; Chuang, Y; Chen, G; Hung, C; Chang, S
   (Taipei, Taiwan)

P256  High sustained virological response rates using imported generic direct-acting antiviral
   treatment for hepatitis C, imported into Australia, UK, Europe and North America
   Hill, A*; Savage, A; Jeffreys, G; Sallie, R; Kennedy, A; Ngoc Nieu, P; Freeman, J; Freeman, J (London,
   UK)

P257  Long-term virologic and serologic response of chronic hepatitis B virus infection to tenofovir
   disoproxil fumarate-containing regimens in HIV-positive patients
   Huang, Y; Su, Y; Liu, W; Chang, S; Sheng, W; Sun, H; Hsieh, S; Chuang, Y; Hung, C*; Chang, S (Hsin-
   Chu, Taiwan)

P258  The emergence of hepatitis C virus genotype 4d infection in men who have sex with men
   Sutcliffe, L*; Thomson, E (Glasgow, UK)

P259  SOF/VEL single-tablet regimen in HCV mono-infected and HIV/HCV co-infected patients:
   comparison of efficacy and safety data from phase 3 clinical trials
   Wyles, D; Brau, N; Naggie, S; Sulkowski, M; Agarwal, K; Patel, K; Afdhal, N; Liu, L; Ding, X; Huang, K;
   Osinusi, A; McNally, J; Brainard, D; Mertens, M*; McHutchison, J (London, UK)

P260  HIV/hepatitis C co-infected patients are significantly more complex to manage than HIV
   mono-infected patients in a large cohort of treatment-naive, HIV-positive individuals
   Dieterich, D*; Fusco, J; Henegar, C; D'Amico, R; Schulman, K; Zelt, S; Lackey, P (New York, USA)

P261  Efficacy of generic direct-acting antiviral treatment for hepatitis C, imported into Russia and
   Eastern Europe
   Hill, A*; Dragunova, J; Korologou-Linden, R; Golovin, S (London, UK)

P262  High sustained virologic response rates using generic direct-acting antiviral treatment for
   hepatitis C, imported into Southeast Asia
   Korologou-Linden, R*; Hill, A; Wardhana, A; Khwairakpam, G (London, UK)

*Indicates presenting author.
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>P263</td>
<td>Is ART use associated with an increased risk of ALT elevation in HIV/HCV co-infected patients over and above what is expected in HIV mono-infected patients? A nested case-control analysis</td>
<td>Shanyinde, M*; Marchetti, G; Bruno, R; Ceccherini-Silberstein, F; Gori, A; De Luca, A; Vecchiet, J; Lichtner, M; Madeeddu, G; Bonfanti, P; d’Arminio Monforte, A; Cozzi-LePri, A</td>
<td>on behalf of the ICONA Foundation cohort (London, UK)</td>
</tr>
<tr>
<td>P264</td>
<td>Long-term trends in HCV treatment uptake, efficacy and liver disease in the SHCS</td>
<td>Béguelin, C*; Sutter, A; Bernasconi, E; Braun, D; Kovari, H; Bucher, H; Stoeckle, M; Cavassini, M; Rougemont, M; Schmid, P; Rauch, A</td>
<td>Bern (Switzerland)</td>
</tr>
<tr>
<td>P265</td>
<td>Effectiveness of all-oral DAAs for HCV genotype 4 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe study</td>
<td>Gonzalez-Garcia, J*; Aldamiz-Echevarria, T; Quereda, C; Hontaño, V; Domínguez-Domínguez, L; Gil-Martin, A; Cruz-Martos, E; Tellez, M; Santos, I; Cuevas-Tascon, G; Gaspar, G; Alvarez-Alvarez, B; Losa, J; Cervero, M; Barros, C; Mosalvo, R; Menendez, M; Belda, L; Calvo, M; Alcaraz, M; Jarrin, I</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>P266</td>
<td>Continued increase of recent hepatitis C virus infections among HIV-positive patients in Taiwan</td>
<td>Liu, W; Su, L; Wu, C; Wu, P; Yang, S; Zhang, J; Chang, H; Chang, S; Liu, C; Sun, H; Hung, C*; Chang, S</td>
<td>Taipei, Taiwan</td>
</tr>
<tr>
<td>P267</td>
<td>Treatment failure with DAAs in chronic hepatitis C: a Portuguese multicenter report</td>
<td>Valente, C*; Casella, M; Faria, D; Aleixo, M; Vaz Pinto, I; Moita, M; Mingo, A; Carvalho, A; Roxo, F; Faísca, R; Proença, P; Poças, J; Prata, M; Marques, N; Saraiva Cunha, J</td>
<td>Coimbra, Portugal</td>
</tr>
<tr>
<td>P268</td>
<td>Seroepidemiology of hepatitis A virus among HIV-positive patients in Taiwan in the setting of acute hepatitis A outbreak in 2015–2016</td>
<td>Chen, G*; Lin, K; Sun, H; Sheng, W; Hsieh, S; Chuang, Y; Hung, C; Chang, S</td>
<td>Taipei, Taiwan</td>
</tr>
<tr>
<td>P269</td>
<td>Different impact of DAA on innate and adaptive cellular immunity in HIV/HCV co-infected and HCV mono-infected patients</td>
<td>Zuccalà, P*; Lichtner, M; Vita, S; Marocco, R; Mascia, C; Savinelli, S; Campagna, M; Mengoni, F; Tieghi, T; Pozzetto, I; D’Ettorre, G; Paolletti, F; Mastroianni, C; Vullo, V</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>P270</td>
<td>Real-life renal impact of ledipasvir/sofosbuvir on a cohort of HIV-infected patients treated with tenofovir combination with a boosted protease inhibitor</td>
<td>Cabo, J*; Garrote, A; Simões, P; Póvoas, D; Gonçalves, R; Ramirez, F; Betkova, S; Seixas, D; Alves, L; Manata, M; Garrido, N; Cardoso, O; Cardoso, S; Lino, S; Martins, T; Matlecz, F</td>
<td>Lisbon, Portugal</td>
</tr>
<tr>
<td>P271</td>
<td>Changes in lipid profile during and after hepatitis C virus (HCV) treatment with direct-acting antiviral (DAA), interferon-free regimens in patients co-infected with HIV</td>
<td>Domínguez-Domínguez, L*; Bisbal, O; Lagarde, M; Matarranz, M; Hernando, A; Rubio, R; Pulido, F</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>P272</td>
<td>HIV/hepatitis C co-infection: successfully treating hepatitis C with direct-acting antivirals and managing those who do not access traditional care</td>
<td>Metcalfe, R*; Bulteel, N; Schofield, J; McGinnity, P; Glover, C; McLean, L; Marra, F; Murphy, A; Peters, E; Bell, D; Fox, R; Thomson, E</td>
<td>Glasgow, UK</td>
</tr>
<tr>
<td>P273</td>
<td>Improving of glycemic control associated with DAAs HCV treatment persists at SVR12</td>
<td>Pavone, P*; d’Ettorre, G; Lichtner, M; Tieghi, T; Marocco, R; Mezzaroma, I; Passavanti, G; Mastroianni, C; Vullo, V</td>
<td>Rome, Italy</td>
</tr>
</tbody>
</table>

*Indicates presenting author.
P274  Ledipasvir/sofosbuvir for 12 or 24 weeks in HCV genotype 1 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe study
Berenguer, J*; Moreno, A; Martín-Carbonero, L; Domínguez, L; Aldámitz-Echevarría, T; Gil-Martín, Á; Cruz-Martos, E; Vergas, J; Santos, I; Benítez, L; De Miguel, J; Troya, J; Álvarez, B; Torres, R; Canalejo, E; Arponen, S; de Guzmán, M; Gotuzzo, L; Calvo, M; Alcaraz, M; Jarrin, I; González-García, J (Madrid, Spain)

P275  Seroepidemiology of hepatitis B virus (HBV) infection among HIV-positive men who have sex with men born in the era of nationwide neonatal HBV vaccination in Taiwan
Huang, Y*; Yang, S; Liu, W; Wu, P; Sun, H; Sheng, W; Hsieh, S; Hung, C; Chang, S (Taipei City, Taiwan)

P276  Liver fibrosis regression in HIV-HCV co-infected individuals after sustained virologic response with HCV direct-acting antivirals
Arias, A*; Lledó, G; Treviño, A; Benítez-Gutierrez, L; Carrasco, I; Cuervas-Mons, V; De Mendoza, C (Madrid, Spain)

P277  Treatment rate for HCV in the DAAs era in HIV co-infected patients: data from an Italian cohort
Cuomo, G*; Puzzolante, C; Mussini, C; Borghi, V (Modena, Italy)

P278  The elderly and direct antiviral agents (DAAs): constraint or challenge?
Fabrizio, C*; Bruno, G; Milano, E; Dell’Acqua, R; Monno, L; Lo Caputo, S; Milella, M; Saracino, A; Angarano, G (Bari, Italy)

P279  Treating HCV-positive Italian inmates with direct-acting antivirals: the clinical experience in three major correctional houses of Milan
Ranieri, R*; Foschi, A; Casana, M; Radice, A; D’Angelo, C; De Bona, A; Bai, F; Lari, C; d’Arminio Monforte, A (Milan, Italy)

P280  Effectiveness of dasabuvir, ombitasvir/paritaprevir/ritonavir (DSV+OBV/PTV/r) for HCV genotype 1 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe study
Gonzalez-Garcia, J*; Montes-Ramirez, M; Dominguez-Dominguez, L; Aldamiz-Echevarria, T; Vivancos, M; Gil-Martin, A; Cruz-Martos, E; Estrada, V; Arias, A; Sanz, J; Gaspar, G; Losa, J; Barros, C; Ruiz-Giardin, J; Gimeno-Garcia, A; Vegas, A; Garcia-Benayas, M; Serrano, R; Calvo, M; Alcaraz, M; Jarrin, I; Berenguer, J (Madrid, Spain)

P281  Response to DAA-based regimens in genotype 4 chronic HCV/HIV co-infected patients in real life: COINFECOVA-2-SEICV study
Minguez, C*; Garcia-Deltoro, M; Flores, J; Montero, M; Carmen, J; Galindo, M; Reus, S; Ballester, J; Usó, J; Ortega, E; SEICV Study Group, for the COINFECOVA-2 SEICV Study Group (Castellón, Spain)

P282  The role of two non-invasive tests to evaluate the liver fibrosis (FIB-4 and transient elastography) and its implications in the different HCV genotypes in a cohort of HIV/HCV co-infected patients
Perez Martinez, L*; Lapresta, C; Gracia, M; Moreno, J; Cecilio, A; Rubio, T; Irigoyen, C; Samperiz, G; Sanjoaquin, I; Blanco, J (Logroño [La Rioja], Spain)

P283  Diversity of hepatitis C virus envelope associated with fibrosis in treatment-naïve patients
Banica, L*; Paraschiv, S; Neaga, E; Gheorghita, V; Batan, I; Vlaiuc, O; Popescu, C; Otelea, D (Bucharest, Romania)

*Indicates presenting author.
<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P284</td>
<td>Ledipasvir/sofosbuvir for 8 or 12 weeks in GT1 HCV-infected, treatment-naïve, non-cirrhotic patients with HIV infection: real-world experience from the MADRID-CoRe study</td>
<td>Berenguer, J*; Gil-Martin, A; Moreno, A; Moreno, F; Dominguez, L; Aldámiz-Echevarría, T; Cruz-Martos, E; Estrada, V; Santos, I; Benítez, L; Sanz, J; Ryan, P; Gaspar, G; Álvarez, B; Losa, J; Jusdado, J; Barros, C; Malmerca, E; Calvo, M; Alcaraz, M; Jarrín, I; González-García, J (Madrid, Spain)</td>
</tr>
<tr>
<td>P285</td>
<td>Effect of mono/dual antiretroviral therapy on HCV and HIV suppression during HCV treatment in HIV/HCV co-infected patients</td>
<td>Martín-Carbonero, L*; Domínguez, L; Bailón, L; Torres, R; Rubio, R; Ron, R; Rico, M; Jiménez-Nacher, I; Moreno, F; González, J; Pulido, F; Montes, M (Madrid, Spain)</td>
</tr>
<tr>
<td>P286</td>
<td>Health resources use in patients with HIV: evidence from Italian administrative databases</td>
<td>Perrone, V*; Sangjorgi, D; Grovato, E; Buda, S; Degli Esposti, I (Ravenna, Italy)</td>
</tr>
<tr>
<td>P287</td>
<td>HCV+ and HIV/HCV+ patients treated with direct antiviral agents (DAAs): to what extent do they differ?</td>
<td>Bruno, G*; Fabrizio, C; Dell’Acqua, R; Milano, E; Milìella, M; Saracino, A; Monno, L; Angarano, G (Bari, Italy)</td>
</tr>
<tr>
<td>P288</td>
<td>Renal safety of boosted PI in HIV/HCV patients on SOF/LDV</td>
<td>Vivancos-Gallego, M*; Moreno, A; Perez Elias, M; Quereda, C; Casado, J; Sanchez-Conde, M; Navas, E; Del Campo, S; Moreno, S (Madrid, Spain)</td>
</tr>
<tr>
<td>P289</td>
<td>Entecavir plus lamivudine as an alternative treatment for co-infected HBV/HIV patients with toxicity on tenofovir therapy</td>
<td>Fontecha-Ortega, M*; Muñoz-Mendoza, V; Monsalvo, M; Mateos, M; Rodríguez-Sagrado, M; Gómez, C; Casado, J (Madrid, Spain)</td>
</tr>
<tr>
<td>P290</td>
<td>Direct-acting antiviral drugs (DAAs) for the treatment of chronic HCV infection in HIV co-infected patients: a monocentric experience in real life</td>
<td>Izzo, I*; Casari, S; Vavassori, A; Nasta, P; Odolini, S; Castelnuovo, F; Bergamasco, A; El Hamad, I; Parainfno, G; Spinetti, A; Zaltro, S; Urbinati, L; Biasi, L; Focà, E; Festa, E; Cristini, G; Castelli, F (Brescia, Italy)</td>
</tr>
<tr>
<td>P291</td>
<td>Daclatasvir (DCV) pharmacokinetics in HCV/HIV co-infected patients co-administered with rilpivirine and other antiretroviral drugs</td>
<td>Barco, A*; Marinario, L; Merli, M; Alcantarini, C; Montrucchio, C; Venderniati, G; Milesi, M; Patti, F; Favata, F; Ariaudo, A; Hasson, H; D’Avolio, A; Uberti-Foppa, C; Di Perri, G; Bonora, S (Turin, Italy)</td>
</tr>
<tr>
<td>P292</td>
<td>Chronic HCV genotype 4 infection in a Portuguese cohort of co-infected HIV patients: treatment with sofosbuvir-based regimens</td>
<td>Brogueira, P*; Moneti, V; Miranda, A; Ventura, F; Baptista, T; Borges, F; Nina, J; Peres, S; Aldir, I; Campos, M; Antunes, I; Pereira, J; Mansinho, K (Lisbon, Portugal)</td>
</tr>
<tr>
<td>P293</td>
<td>Mortality during direct-acting antiviral therapy in HCV/HIV patients with cirrhosis</td>
<td>Vivancos-Gallego, M*; Moreno, A; Perez Elias, M; Quereda, C; Casado, J; Gomez Ayerbe, C; Sanchez-Conde, M; Del Campo, S; Moreno, S (Madrid, Spain)</td>
</tr>
<tr>
<td>P294</td>
<td>Characteristics and effectiveness in HCV mono-infected and HIV-HCV co-infected cirrhotic patients receiving oral direct-acting antiviral (DAA) regimens interferon-free therapies in southern Spain</td>
<td>Alcaraz, B; Vera, F; Escribano, P*; Rojano, R; Jimeno, A; Ruiz, E; Garcia, A; Trujillo, J; Cobos, N; Bernai, E; Alcalde, M; Garcia, J; Martinez, O; Capozzi, M; Martinez, L (Cartagena, Spain)</td>
</tr>
</tbody>
</table>

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P295  Chronic hepatitis C treatment with direct antiviral drugs in mono- and HIV co-infected patients: a real-life experience in an infectious diseases department at a hospital in Portugal
Cabo, J*; Martins, T; Garrido, N; Betkova, S; Manata, M; Alves, L; Cardoso, S; Cardoso, O; Gonçalves, R; Garrote, A; Simões, P; Ramirez, F; Seixas, D; Lino, S; Maltez, F; Póvoas, D (Lisbon, Portugal)

P296  Chronic HCV treatment with DAA: what changes when treating cirrhotic patients – a Portuguese cohort real-life experience
Miranda, A*; Azevedo, T; Cruz, I; Ventura, F; Baptista, T; Borges, F; Peres, S; Aldir, I; Nina, J; Antunes, I; Campos, M; Pereira, J; Mansinho, K (Lisbon, Portugal)

P297  Chronic hepatitis C in HIV-infected patients: treatment in real life with new generation direct-acting antivirals in a Portuguese centre
Silva-Pinto, A; Ruas, R; Abreu, I; Ceia, F; Figueiredo, C; Carvalho, A; Santos, A; Soares, J; Piñeiro, C; Serrão, R*; Sarmento, A (Porto, Portugal)

P298  Impact of HCV RNA kinetics in SVR12 in a cohort of HIV/HCV co-infected patients treated with DAAAs in a ‘real-life’ setting
Cavinato, S; Zuin, S; Marini, G; Barbaro, F; Parisi, S; Cattelan, A* (Padua, Italy)

P299  CD4 cell count before chronic hepatitis C (HCV) treatment with direct-acting antivirals (DAAs) and at the end of follow-up in HCV/HIV co-infected patients
Mendez, J; Soeiro, T; Marques, M; Gonçalves, C; Tavares, A; Horta, A; Vasconcelos, O; Seabra, J; Abreu, M; Sarmento e Castro, R (Porto, Portugal)

P300  Testing for HCV and HIV at baseline visit due to post-exposure prophylaxis
Kowalska, J*; Pietraszkiewicz, E; Firlag-Burkacka, E; Pyziak-Kowalska, K; Horban, A (Warsaw, Poland)

Clinical Pharmacology

P301  Interactions between HIV and HCV therapies: how common and who wins?
Torkington, A*; Barnes, J; Cripps, S; Lee, K; Marshall, N; Morgan, H; Pratt, A; Sayers, I; Swade, J; Swaden, L; Selby, P; Vaghjiani, T; Zimmer, M; Bhagani, S; Collier, J; Macdonald, D; Nelson, M; Prince, M; Wright, M; Ustianowski, A (Manchester, UK)

P302  Efavirenz significantly decreases etonogestrel exposure: results of a bidirectional pharmacokinetic evaluation of efavirenz- and nevirapine-based antiretroviral therapy plus etonogestrel contraceptive implants
Chappell, C*; Scarsi, K; Nakalema, S; Chen, B; Riddler, S; Cohn, S; Darin, K; Achilles, S; Lamorde, M (Pittsburgh, USA)

P303  Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Cattaneo, D*; Minisci, D; Cozzi, V; Riva, A; Meraviglia, P; Clementi, E; Rizzardini, G; Gervasoni, C (Milan, Italy)

P304  Determinants of dolutegravir plasma concentrations in the clinical setting
Alcantarini, C; Calcagno, A*; Marinaro, L; Ferrara, M; Milesi, M; Trentalange, A; Barco, A; Montrucchio, C; De Nicolò, A; Ariaudo, A; Favata, F; D’Avolio, A; Di Perri, G; Bonora, S (Turin, Italy)

P305  Pharmacokinetics (PK) of darunavir/ritonavir (DRV/RTV) with tenofovir DF/emtricitabine (TDF/FTC) or raltegravir (RAL) in HIV-infected adults enrolled in the NEAT001/ANRS143 study and relationship with virological response
Bonora, S; Stohr, W; D’Avolio, A; Cursley, A; Molina, J; Faetkenheuer, G; Vandekerckhove, L; Di Perri, G; Pozniak, A; Richert, L; Raffi, F; Boffito, M* (London, UK)

*Indicates presenting author.
P306  Evaluation of the drug-drug interaction (DDI) potential between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and atorvastatin
Custodio, J*; West, S; SenGupta, D; Zani, A; Humeniuk, R; Ling, K; Fordyce, M; Kearney, B (Foster City, USA)

P307  Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice
Elliot, E*; Amara, A; Pagani, N; Else, L; Moyle, G; Schoolmeesters, A; Higgs, C; Khoo, S; Boffito, M (London, UK)

P308  Association of SLCO1B1 521T>C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study
Gurjar, R*; Boffito, M; D’Avolio, A; Schwimmer, C; Yazdanpanah, Y; Doroana, M; Di Perri, G; Bonora, S; Pozniak, A; Richert, L; Raffi, F; Owen, A (Liverpool, UK)

P309  When food can make the difference: the case of elvitegravir-based coformulation
Gervasoni, C*; Baldelli, S; Minisci, D; Meraviglia, P; Clementi, E; Galli, M; Cattaneo, D (Milan, Italy)

P310  Impact of food on the bioavailability of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (DCFTA), the first protease inhibitor-based complete HIV-1 regimen
Crauwels, H; Baugh, B*; Van Landuyt, E; Vanveggel, S; Hijzen, A; Opsturnon, M (Raritan, USA)

P311  Prevalence of drug-drug interactions (DDI) and its impact on durability among patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/C/F/T) and concomitant medication
Gomez-Ayerbe, C; Del Campo, S; Vivancoos, M; Gaspar, G; Moreno, A; Martin, A; Romero, A; Jimenez, P; Cervero, M; Rodriguez-Sagrado, M; Serrano, R; Muriel, A; Peréz Elías, M* (Madrid, Spain)

P312  Relationships between dolutegravir plasma-trough concentrations, UGT1A1 genetic polymorphisms and side-effects of the central nervous system in Japanese HIV-1-infected patients
Yagura, H*; Watanabe, D; Ashida, M; Nakauchi, T; Tomishima, K; Togami, H; Hirano, A; Sako, R; Doi, T; Yoshino, M; Takahashi, M; Yamazaki, K; Uehira, T; Shirasaka, T (Osaka, Japan)

P313  S-protein thiol-omics to assess the redox-modulation effects of antiretroviral drugs
Correia, M; Dias, C; Caixas, U*; Grilo, N; Lemos, A; Trigo, D; Pacheco, P; Monteiro, E; Soto, K; Diogo, L; Pereira, S (Lisbon, Portugal)

P314  Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI)
Podzamczer, D; Tashima, K; Daar, E; McGowan, J; Campbell, T; Slim, J; Thompson, M; Guo, S; Borg, P; Haubrich, R; Das, M; McNicholl, I*; McCallister, S (Foster City, USA)

P315  Real-world antiretroviral plasma levels in HIV-positive patients treated with sofosbuvir-containing DAA for hepatitis C infection
Tempestilli, M; Fabbri, G*; Timelli, L; Zaccarelli, M; Bellagamba, R; Cicalini, S; Lupi, F; Gallo, A; Libertone, R; Fazio, S; Antinori, A; Ammassari, A (Rome, Italy)

P316  Detection and analysis of antiretroviral medication errors by a clinical pharmacist in hospitalized HIV patients
Pablos Bravo, S; García Muñoz, C; Pulido, F*; Lázaro Cebas, A; Ferrari Piquero, J (Madrid, Spain)

P317  Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single-centre cohort of HIV-positive patients
Salvaggio, S; Giacomelli, A*; Falvella, F; Oreni, L; Meraviglia, P; Atzori, C; Clementi, E; Galli, M; Rusconi, S (Milan, Italy)

*Indicates presenting author.
### POSTER PRESENTATIONS (continued)

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P318</td>
<td>Prevalence of drug-drug interactions involving antiretroviral treatment: impact of the integrase inhibitor class</td>
<td>Messiaen, P*; Baecke, C; van der Hilst, J (Hasselt, Belgium)</td>
</tr>
<tr>
<td>P319</td>
<td>Temporal trend of the plasma level of efavirenz: comparison between CYP2B6-516 GG and GT genotype</td>
<td>Wong, C*; Chan, P; Lee, S (Hong Kong, Hong Kong)</td>
</tr>
</tbody>
</table>

### Community Initiatives

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P320</td>
<td>European survey on doctor-patient relationship</td>
<td>Kelly, D*; Jachnowitsch, K; Raskevich, Y; Petkovic, N; West, B; Uyanik, D; Hodgson, I; Darakjian, V; Garrido Fuentes, J; Morton, J; Mukelabai, N; Bleak, S; Dessler, S; Mladenovic, N; Antoniadi, C (Brussels, Belgium)</td>
</tr>
<tr>
<td>P321</td>
<td>HIV testing in the community: responding to the Glasgow outbreak</td>
<td>Middleton, L* (Glasgow, UK)</td>
</tr>
<tr>
<td>P322</td>
<td>Factors influencing and associated with the decision to join in Thailand's first online supervised HIV self-testing and counseling initiative</td>
<td>Anand, T*; Nipolprasert, C; Kerr, S; Apompong, T; Ananworanich, J; Phanuphap, P; Phanuphap, N (Bangkok, Thailand)</td>
</tr>
<tr>
<td>P323</td>
<td>Ways in which legal and regulatory barriers hinder the HIV care continuum and 90/90/90 target across Europe</td>
<td>Power, L*; Hows, J; Raben, D; Finne Jakobsen, S; Croxford, S (Cardiff, UK)</td>
</tr>
<tr>
<td>P324</td>
<td>Integrated HIV, hepatitis B and hepatitis C testing during the 2015 European testing week</td>
<td>Sperle, I*; West, B; Delpech, V; Noori, T; Zakowicz, A; Von Lingen, A; Dedes, N; Farrel, J; Daamen, C; Begovac, J; Power, L; James, C; Collins, B; Kovacs, T; Fernandes, R; Dominković, Z; Raben, D (Copenhagen, Denmark)</td>
</tr>
</tbody>
</table>

### Models of Care

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P327</td>
<td>Modelling the cost-effectiveness of HIV care in Poland shows clear benefits, while transmission risk is considered in the calculations</td>
<td>Kowalska, J*; Wójcik, G; Rutkowski, J; Ankiersztejn-Bartczak, M; Siewaszewicz, E (Warsaw, Poland)</td>
</tr>
<tr>
<td>P328</td>
<td>Targeting HIV testing at a population level: cost-effectiveness of three approaches</td>
<td>Gomez Ayerbe, C*; Muriel, A; Reverte, C; Perez Elias, P; Del Campo, S; Vivancos, M; Santos, C; Calonge, M; Uranga, A; Moreno, A; Moreno, S; Casado, J; Perez Elias, M (Madrid, Spain)</td>
</tr>
<tr>
<td>P329</td>
<td>HIV linkage to care: impact of a proactive intervention in a health area of Spain</td>
<td>del Campo, S*; Gomez Ayerbe, C; Vivancos Gallego, M; Moreno Zamora, A; Casado Osorio, J; Loza de Bobadilla, E; Galán Montemayor, J; Rodríguez Dominguez, M; Dronda Nuñez, F; Sanchez Conde, M; Moreno Guillén, S; Pérez Elias, M (Madrid, Spain)</td>
</tr>
<tr>
<td>P331</td>
<td>Retention of mother-baby pairs in care and treatment through mother-baby care point initiative in Eastern Uganda</td>
<td>Abwola Olwedo, M*; Lukoda, N; Crandall, B (Mbale, Uganda)</td>
</tr>
<tr>
<td>P332</td>
<td>Efficiency of antiretroviral therapy in Russia</td>
<td>Pokrovskaya, A*; Kozyrina, N; Guschina, U; Suzorova, Z; Yurin, O; Pokrovskiy, V (Moscow, Russian Federation)</td>
</tr>
</tbody>
</table>

*Indicates presenting author.
POSTER PRESENTATIONS (continued)

P333  Closing the gap of perinatal HIV infection in Hong Kong  
Wong, C*; Lin, W; Wong, K (Hong Kong, Hong Kong)

P334  ‘The first 90’: how close can we get with home-based HIV testing? First results from recruitment for the CASCADE trial in rural Lesotho  
Labhardt, N*; Ringera, I; Lejone, T; Muhairwe, J; Fritz, C; Klimkait, T; Glass, T (Basel, Switzerland)

P335  Characterisation of an inmate population followed in an infectious diseases department in the centre of Portugal  
Casella, M*; Ascenção, B; Goes, A; Pinto Luís, N; Messias, A; Brito, A; Joana, S; Poças, J (Setúbal, Portugal)

P336  Rationales for indicator conditions based HIV testing data from the Emergency Department in the Hospital for infectious diseases in Warsaw  
Pyziak-Kowalska, K*; Kowalska, J; Horban, A (Warsaw, Poland)

P337  The changing epidemiology of newly diagnosed HIV-infected adults in New York City  
Patterson, B*; Zucker, J; Ellman, T; Morrison, E; Sobieszczyk, M (New York, USA)

P338  Reasons for transferring HIV care in London  
Ahmed, N; Scott, D; Waters, L*; Matin, N; Whitlock, G (London, UK)

P339  Atmosphere of risk or family-like support? Alternative patient experiences of decentralized care in North Central Nigeria  
Kolawole, G*; Gilbert, H; Dadem, N; Agaba, P; Genberg, B; Agbaji, O; Okonkwo, P; Ware, N (Jos, Nigeria)

Late Presenters

P340  High mortality attributable to late presentation and delayed ART initiation in HIV-infected adults receiving care in Latin America  
Belaunzarán-Zamudio, P*; Shepherd, B; Caro-Vega, Y; Cortés, C; Crabtree-Ramirez, B; Grinsztejn, B; Gotuzzo, E; Mejía, F; Padgett, D; Pape, J; Rebeiro, P; Rouzier, V; Veloso, V; Wagner-Cardoso, S; McGowan, C; Sierra-Madero, J (Mexico City, Mexico)

P341  Insights into missed opportunities for earlier testing in newly diagnosed patients referred for HIV care to a Swiss teaching hospital between 2010 and 2015  
Lhopitallier, L*; Moulin, E; Cavassini, M; Darling, K (Lausanne, Switzerland)

P342  Is it acceptable to ignore national testing guidelines? Current testing practice in Lothian 8 years after BHIVA national testing guidelines were published  
Cevik, M*; Raha, D; Mutch, C; Leen, C (Edinburgh, UK)

P343  HIV late presenters: a retrospective cohort study on an outpatient clinic in Lisbon, 2010–2014  
Cota-Medeiros, F*; Afonso, C; Zagalo, A; Caldeira, L (Lisbon, Portugal)

P344  Clinical characteristics of newly diagnosed HIV-infected patients and risk factors for late presentation: a Portuguese cohort  
Veiga Ferraz, R*; Almeida, F; Duro, R; Pereira, N; Pinero, C; Caldas, C; Serrão, R; Sarmento, A (Porto, Portugal)

*Indicates presenting author.
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P345</td>
<td>Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin</td>
<td>Gelpi, M*; Hartling, H; Thorsteinsson, K; Gerstoft, J; Ullum, H; Nielsen, S (Copenhagen, Denmark)</td>
</tr>
<tr>
<td>P346</td>
<td>Neurosymptomatic cerebrospinal fluid (CSF) viral escape (aCVE) is associated with increased intrathecal immune activation, but not with CSF signs of neuronal injury and alteration of CSF/serum albumin ratio</td>
<td>Pinnetti, C*; Fedele, V; Carta, S; Lorenzini, P; Mazzotta, V; Bordoni, V; Baldini, F; Grisetti, S; Capobianchi, M; Martini, F; Ceccherini-Silberstein, F; Ammassari, A; Perno, C; Antinori, A (Rome, Italy)</td>
</tr>
<tr>
<td>P347</td>
<td>Cardiovascular risk in HIV-positive subjects: analyses of T-cell phenotype and CD49d expression</td>
<td>Zingaropoli, M*; D’Abramo, A; Iannetta, M; Oliva, A; d’Ettorre, G; Lichtner, M; Mastroianni, C; Ciardi, M; Vullo, V (Rome, Italy)</td>
</tr>
<tr>
<td>P348</td>
<td>Baseline myeloid and lymphoid activation markers can predict time to viral load reduction under 50 copies/mL and CD4 recovery, respectively, after highly-active antiretroviral therapy initiation</td>
<td>Iannetta, M*; Lichtner, M; Rossi, R; Savinelli, S; Vita, S; Mascia, C; Zuccalà, P; Marocco, R; Zingaropoli, M; Ciardi, M; d’Ettorre, G; Mastroianni, C; Vullo, V (Rome, Italy)</td>
</tr>
<tr>
<td>P349</td>
<td>Impact of oestrogen plasma levels in modulation of immune activation among HIV-infected women and men undergoing successful antiretroviral therapy</td>
<td>Marocco, R*; Lichtner, M; Tieghi, T; Belvisi, V; Pozzetto, I; Mascia, C; Zuccalà, P; Rossi, R; Mengoni, F; Mastroianni, C (Latina, Italy)</td>
</tr>
<tr>
<td>P350</td>
<td>Active TGF-β 1 may be involved in viral suppression during ART in HIV-1-infected patients</td>
<td>Maina, E*; Bukusi, E; Sedegah, M; Larney, M; Ampofo, W (Accra, Ghana)</td>
</tr>
<tr>
<td>P351</td>
<td>Geno2pheno [coreceptor-hiv2]: a new diagnostic tool for the genotypic determination of HIV-2 coreceptor usage</td>
<td>Döring, M*; Borrego, P; Büch, J; Martins, A; Friedrich, G; Camacho, R; Eberle, J; Kaiser, R; Lengauer, T; Taveira, N; Pfeifer, N (Saarbrücken, Germany)</td>
</tr>
<tr>
<td>P352</td>
<td>High rates of multi-class drug resistance in HIV-1-infected individuals monitored with CD4 cell count in Uganda</td>
<td>von Braun, A*; Scherer, A; Sekaggya, C; Kirangwa, J; Ssemwanga, D; Kaleebu, P; Günthard, H; Kamburu, A; Casteleyn, B; Fehr, J (Kampala, Uganda)</td>
</tr>
<tr>
<td>P353</td>
<td>Prevalence and impact of transmitted drug resistance in recent HIV-1 infections, Germany 2013–2015</td>
<td>Hauser, A*; Hofmann, A; Hanke, K; Bremer, V; Bartmeyer, B; Kücherer, C; Bannert, N (Berlin, Germany)</td>
</tr>
<tr>
<td>P354</td>
<td>Higher rates for transmission of NNRTI-resistant viruses for subtype A versus subtype B strains in Southern Greece</td>
<td>Kostaki, E; Sympsa, V; Nikolopoulos, G; Gargalianos, P; Xylomenos, G; Lazanas, M; Chini, M; Skoutelis, A; Papastampopoulos, V; Antoniadou, A; Papadopoulos, A; Psychogiou, M; Daikos, G; Chrysos, G; Paparizos, V; Kourkounti, S; Sambatakou, H; Sipsas, N; Lada, M; Panagopoulos, P; Maltezos, E; Hatziakis, A; Paraskevis, D* (Athens, Greece)</td>
</tr>
<tr>
<td>P355</td>
<td>The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness and durable anti-HIV immune responsiveness</td>
<td>Wainberg, M*; Mesplede, T (Montreal, Canada)</td>
</tr>
</tbody>
</table>

*Indicates presenting author.
P356  Low prevalence of pre-treatment HIV-1 drug resistance in Ugandan adults
von Braun, A*; Sekaggya, C; Scherrer, A; Magambo, B; Ssemwanga, D; Kaleebu, P; Günthard, H; Kambugu, A; Fehr, J; Castelnuovo, B (Kampala, Uganda)

P357  Prevalence of resistance mutations to rilpivirine and etravirine in people starting antiretrovirals in Argentina
Bissio, E*; Barbás, M; Bouzas, M; Cudolá, A; Falistocco, C; Salomón, H (Buenos Aires, Argentina)

P358  Frequency of additional resistance relevant mutations in 2% and 1% population proportions in next-generation sequencing (NGS) in routine HIV-1 resistance diagnostics
Ehret, R*; Moritz, A; Schuetze, M; Obermeier, M (Berlin, Germany)

P359  Impact of baseline NNRTI resistance in antiretroviral-naïve patients in a large urban clinic
Steinberg, S*; Crouzet, F; Sandler, I; Variano, B; Smith, G; Kovacs, C; Brunetta, J; Chang, B; Merkley, B; Tilley, D; Fletcher, D; Acsai, M; Knox, D; Sharma, M; Loutfy, M (Toronto, Canada)

P360  Enhanced surveillance to study HIV-1 drug resistance among naïve individuals in Southern Greece: the added value of molecular epidemiology to public health
Paraskevis, D*; Kostaki, E; Magiorkinis, E; Gargalianos, P; Xylomenos, G; Lazanas, M; Chini, M; Skoutelis, A; Papastamopoulos, V; Antoniadou, A; Papadopoulos, A; Psychogiu, M; Daikos, G; Zavitsanou, A; Chrysos, G; Paparizos, V; Kourkounti, S; Oikonomopoulou, M; Sambatakou, H; Sipsas, N; Lada, M; Panagopoulos, P; Maltezos, E; Drimis, S; Hatzakis, A (Athens, Greece)

P361  Transmission patterns of HIV-1 subtype A resistant strains across Greece: evidence for country and regional level transmission networks
Paraskevis, D*; Skoura, L; Kostaki, E; Gargalianos, P; Xylomenos, G; Lazanas, M; Chini, M; Metallidis, S; Skoutelis, A; Papastamopoulos, V; Antoniadou, A; Papadopoulos, A; Psychogiu, M; Daikos, G; Pilalas, D; Zavitsanou, A; Chrysos, G; Paparizos, V; Kourkounti, S; Chatzidimitriou, D; Sambatakou, H; Sipsas, N; Lada, M; Panagopoulos, P; Maltezos, E; Drimis, S; Hatzakis, A (Athens, Greece)

P362  Occurrence and risk factors for primary integrase resistance-associated mutations in Austria in the years 2008–2013
Zoufaly, A*; Kraft, C; Schmidbauer, C; Puchhammer, E (Vienna, Austria)

P363  Transmission of HIV-1 drug resistance in Tel Aviv, Israel, 2010–2015
Turner, D*; Girshengorn, S; Braun, A; Tau, L; Leshno, A; Alon, D; Pupko, T; Zeldis, I; Matus, N; Gielman, S; Ahsanov, S; Schweitzer, I; Avidor, B (Tel Aviv, Israel)

P364  Development of T66I-mediated integrase inhibitor cross-resistance against elvitegravir under dolutegravir-containing first-line therapy
Wiesmann, F*; Däumer, M; Naeth, G; Knechten, H; Braun, P; Rump, J (Aachen, Germany)

P365  Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing regimens in Taiwan: a multicenter cohort study
Cheng, C*; Su, Y; Tsai, M; Yang, C; Liu, W; Cheng, S; Sun, H; Hung, C; Chang, S (Taoyuan, Taiwan)

P366  Association of therapeutic failure with low-level viremia in HIV-infected patients in the Arevir/RESINA cohort in Germany
Lübke, N*; Pironti, A; Knops, E; Schülder, E; Jensen, B; Oette, M; Esser, S; Lengauer, T; Kaiser, R (Düsseldorf, Germany)

P367  Drug resistance mutations (DRM) among pregnant HIV-positive women in the Duesseldorf University Hospital, Germany, 2009–2016
Haars, U*; Luebke, N; Jensen, B; Haeussinger, D (Essen, Germany)

*Indicates presenting author.
P368 Prevalence of HIV type 1 drug resistance mutations in treatment-naïve patients participating in the GARDEL study
Figueroa, M*; Patterson, P; Cahn, P; Andrade-Villanueva, J; Arribas, J; Gatell, J; Lama, J; Norton, M; Sierra Madero, J; Sued, O; Rolon, M (Buenos Aires, Argentina)

P369 High prevalence of transmitted antiretroviral drug resistance in newly HIV-1 diagnosed Cuban patients
Perez Santos, L*; Machado, L; Kouri Cardella, V; Diaz, H; Aragones, C; Aleman, Y; Silva, E; Correa, C; Blanco de Armas, M; Perez, J; Dubed, M; Soto, Y; Ruiz, N; Limia, C; Nibot, C; Valdés, N; Ortega, M; Romay, D; Baños, Y; Rivero, B; Campos, J (Havana, Cuba)

P370 Viroseq protocol optimized for the detection of HIV-1 drug mutations in patients with low viral load
Monteiro, F*; Tavares, G; Ferreira, M; Amorim, A; Bastos, P; Rocha, C; Hortelão, D; Vaz, C; Koch, C; Araujo, F; Serrão, R; Sarmento, A (Porto, Portugal)

P371 The role of presepsin (sCD14-ST) as an indirect marker of microbial translocation and immune activation
Paola, C*; Zuccaro, V; Cima, S; Sacchi, P; Bruno, R (Pavia, Italy)

P372 CRF19_cpx variant emergence in a cluster in naïve patients of southern Spain: clinical and phylogenetic characterization
González-Domenech, C*; Viciana, I; Mayorga, M; Palacios, R; de la Torre, J; Jarilla, F; Castaño, M; del Arco, A; Márquez, M; Clavijo, E; Santos, J (Málaga, Spain)

P373 One-step real-time PCR for HIV-2 group A and B RNA plasma viral load in LightCycler 2.0
Bastos, P; Monteiro, F*; Tavares, G; Amorim, A; Ferreira, M; Hortelão, D; Rocha, C; Vaz, C; Koch, C; Araujo, F; Serrão, R; Sarmento, A (Porto, Portugal)

P374 The association between high pre-HAART CD8 cell counts and poorer immunological outcome following antiretroviral therapy
Wong, C*; Wong, N; Lee, S (Hong Kong, Hong Kong)

*Indicates presenting author.